KSCP
APFCP
SIUCP-ETS
NSCRD
Search
- Page Path
- HOME > Search
Original Articles
Colorectal cancer
- Oncologic outcomes and associated factors of colon cancer patients aged 70 years and older
- Byeo Lee Lim, In Ja Park, Jun-Soo Ro, Young Il Kim, Seok-Byung Lim, Chang Sik Yu
- Ann Coloproctol. 2025;41(3):198-206. Published online August 5, 2024
- DOI: https://doi.org/10.3393/ac.2023.00367.0052
- 6,813 View
- 87 Download
- 3 Web of Science
- 5 Citations
-
Abstract
PDF
Supplementary Material - Purpose
The aim of this study was to examine the prognosis and associated risk factors, including adjuvant chemotherapy (CTx), in elderly patients with colon cancer.
Methods
This retrospective study included patients who underwent radical resection for colon cancer between January 2010 and December 2014 at Asan Medical Center. The effects of stage, risk factors, and chemotherapy on overall survival (OS) and recurrence-free survival (RFS) were compared in patients aged ≥70 and <70 years.
Results
Of 3,313 patients, 933 (28.1%) was aged ≥70 years. Of the 1,921 patients indicated for adjuvant CTx, 1,294 of 1,395 patients (92.8%) aged <70 years and 369 of 526 patients (70.2%) aged ≥70 years received adjuvant CTx. Old age (≥70 years) was independently associated with RFS in overall cohort. Among patients aged ≥70 years indicated for adjuvant CTx, the 5-year OS (81.6% vs. 50.4%, P<0.001) and RFS (82.9% vs. 67.4%, P=0.025) rates were significantly higher in those who did than did not receive adjuvant CTx. Additionally, adjuvant CTx was confirmed as independent risk factor of both OS and RFS in patients aged ≥70 years indicated for adjuvant CTx.
Conclusion
Old age was associated with poor RFS and adjuvant CTx had benefits in OS as well as RFS in elderly patients eligible for adjuvant CTx. -
Citations
Citations to this article as recorded by
- Immunological changes and recovery-related factors in older patients with colon cancer: A pilot trial
Byeo Lee Lim, Young Il Kim, Jong Lyul Lee, Chan Wook Kim, Yong Sik Yoon, Yousun Ko, Kyung Won Kim, In Ja Park
Journal of Geriatric Oncology.2025; 16(3): 102200. CrossRef - Stage II-III colorectal cancer in geriatric patients: Clinicopathological features and chemotherapy utilization
Yakup Duzkopru, Özlem Doğan
Turkish Journal of Clinics and Laboratory.2025; 16(1): 118. CrossRef - Does Oxaliplatin-based Adjuvant Therapy Benefit Older Colorectal Cancer Patients?
Peter Hofland
Onco Zine - The International Oncology Network.2025;[Epub] CrossRef - Early detection of anastomotic leakage in colon cancer surgery: the role of early warning score and C-reactive protein
Gyung Mo Son
Annals of Coloproctology.2024; 40(5): 415. CrossRef - Efficacy of Neoadjuvant Hypofractionated Chemoradiotherapy in Elderly Patients with Locally Advanced Rectal Cancer: A Single-Center Retrospective Analysis
Jae Seung Kim, Jaram Lee, Hyeung-min Park, Soo Young Lee, Chang Hyun Kim, Hyeong Rok Kim
Cancers.2024; 16(24): 4280. CrossRef
- Immunological changes and recovery-related factors in older patients with colon cancer: A pilot trial
Colorectal cancer
- Lymphovascular invasion in colorectal cancers: can we predict it preoperatively?
- Elbrus Zarbaliyev, Nihan Turhan, Sebahattin Çelik, Mehmet Çağlıkülekçi
- Ann Coloproctol. 2024;40(3):245-252. Published online June 25, 2024
- DOI: https://doi.org/10.3393/ac.2023.00458.0065
- 4,485 View
- 191 Download
- 1 Citations
-
Abstract
PDF
- Purpose
This study aimed to investigate preoperative predictors of lymphovascular invasion (LVI), which is a poor prognostic factor usually detected postoperatively in patients with colorectal cancer.
Methods
Results for all patients operated on for colorectal cancer between January 1, 2006, and December 31, 2021, were retrospectively analyzed. Potential preoperative factors and postoperative pathology results were recorded. The patients were categorized as those with LVI and those without LVI. Potential factors that may be associated with LVI were compared between the 2 groups.
Results
The study included 335 patients. The incidence of LVI was 3.11 times higher in patients with ascending colon tumors (odds ratio [OR], 3.11; 95% confidence interval [CI], 1.34–7.23; P=0.008) and 4.28 times higher in those with metastatic tumors (OR, 4.28; 95% CI, 2.18–8.39; P<0.001). Diabetes mellitus was inversely related to LVI in colorectal cancer patients; specifically, LVI was 56% less common in colorectal cancer patients with diabetes mellitus, irrespective of its duration (OR, 0.44; 95% CI, 0.25–0.76; P<0.001).
Conclusion
The presence of preoperative LVI in colorectal cancer patients is difficult to predict. In particular, the effect of the effect of factors such as chronic disease accompanied by microvascular pathologies on LVI is still unclear. Advances in the neoadjuvant treatment of colorectal cancer patients, who are becoming more widespread every day, will encourage the investigation of different methods of preoperatively predicting LVI as a poor prognostic factor in these patients. -
Citations
Citations to this article as recorded by- Immunohistochemical Expression of MLH1, PMS2 and P53 in Colorectal Carcinoma with Clinicopathologic Correlation
Saif Raghad Saleem Alhamadani, Zainab Khalid Shehab Almukhtar
Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ).2025; 9(1): 222. CrossRef
- Immunohistochemical Expression of MLH1, PMS2 and P53 in Colorectal Carcinoma with Clinicopathologic Correlation
Colorectal cancer
- Impact of consolidation chemotherapy in poor responders to neoadjuvant radiation therapy: magnetic resonance imaging–based clinical-radiological correlation in high-risk rectal cancers
- Swapnil Patel, Suman Ankathi, Purvi Haria, Mufaddal Kazi, Ashwin L. Desouza, Avanish Saklani
- Ann Coloproctol. 2023;39(6):474-483. Published online December 21, 2023
- DOI: https://doi.org/10.3393/ac.2023.00080.0011
- 3,367 View
- 115 Download
- 3 Web of Science
- 3 Citations
-
Abstract
PDF
- Purpose
The current study was conducted to examine the role of consolidation chemotherapy after neoadjuvant radiation therapy (NART) in decreasing the involvement of the mesorectal fascia (MRF) in high-risk locally advanced rectal cancers (LARCs).
Methods
In total, 46 patients who received consolidation chemotherapy after NART due to persistent MRF involvement were identified from a database. A team of 2 radiologists, blinded to the clinical data, studied sequential magnetic resonance imaging (MRI) scans to assess the tumor response and then predict a surgical plan. This prediction was then correlated with the actual procedure conducted as well as histopathological details to assess the impact of consolidation chemotherapy.
Results
The comparison of MRI-based parameters of sequential images showed significant downstaging of T2 signal intensity, tumor height, MRF involvement, diffusion restriction, and N category between sequential MRIs (P < 0.05). However, clinically relevant downstaging (standardized mean difference, > 0.3) was observed for only T2 signal intensity and diffusion restriction on diffusion-weighted imaging. No clinically relevant changes occurred in the remaining parameters; thus, no change was noted in the extent of surgery predicted by MRI. Weak agreement (Cohen κ coefficient, 0.375) and correlation (Spearman rank coefficient, 0.231) were found between MRI-predicted surgery and the actual procedure performed. The comparison of MRI-based and pathological tumor response grading also showed a poor correlation.
Conclusion
Evidence is lacking regarding the use of consolidation chemotherapy in reducing MRF involvement in LARCs. The benefit of additional chemotherapy after NART in decreasing the extent of planned surgery by reducing margin involvement requires prospective research. -
Citations
Citations to this article as recorded by- Survival benefit of adjuvant chemotherapy in high-risk patients with colon cancer regardless of microsatellite instability
Sung Uk Bae, Jong Lyul Lee, Chun-Seok Yang, Eun Jung Park, Soo Yeun Park, Chang Woo Kim, Woong Bae Ji, Gyung Mo Son, Yoon Dae Han, So Hyun Kim, Min Sung Kim, Youn Young Park, Kyung Ha Lee, Chang Hyun Kim, Gi Won Ha, JaeIm Lee, Kyeong Eui Kim, Woon Kyung J
European Journal of Surgical Oncology.2025; 51(6): 109674. CrossRef - Non-operative management of locally advanced rectal cancer with an emphasis on outcomes and quality of life: a narrative review
In Ja Park
Ewha Medical Journal.2025; 48(3): e40. CrossRef - The conundrum of total neoadjuvant therapy in rectal cancer
Devesh S. Ballal, Tejas P. Vispute, Avanish P. Saklani
Colorectal Disease.2024; 26(5): 1068. CrossRef
- Survival benefit of adjuvant chemotherapy in high-risk patients with colon cancer regardless of microsatellite instability
Review
Colorectal cancer
- Total neoadjuvant therapy for rectal cancer: evidence and challenge
- Suk-Hwan Lee
- Ann Coloproctol. 2023;39(4):301-306. Published online August 29, 2023
- DOI: https://doi.org/10.3393/ac.2023.00269.0038
- 11,720 View
- 234 Download
- 8 Web of Science
- 9 Citations
-
Abstract
PDF
- Recent advances in the management of rectal cancer have dramatically changed the clinical practice of colorectal surgeons because the main focus of rectal cancer treatment has changed from sphincter-saving to an organ-preserving strategies. Modifying the delivery of systemic chemotherapy to improve patients’ survival is another progress in colorectal cancer management, known as total neoadjuvant therapy (TNT). TNT is a new strategy used by colorectal surgeons to improve the quality of life and survival of patients after treatment. TNT poses limitations or obstacles, such as overtreatment issues in patients with stage I rectal cancer. However, considering the quality-of-life issues in patients with low-lying rectal cancer necessitating a permanent colostomy, the indication for TNT will be expanded. This review summarizes the recently conducted clinical trials and foresees future perspectives on TNT.
-
Citations
Citations to this article as recorded by- Reply to the Letter to the Editor ‘Circulating tumor DNA after definitive therapy for locally advanced rectal cancer’ by Drs Sorscher and Rocha Lima
A. Bercz, J.J. Smith, P.B. Romesser
Annals of Oncology.2025; 36(2): 224. CrossRef - Neoadjuvant therapy for colorectal cancer from 2015 to 2024: a visual analysis and bibliometric analysis
Boyu Kang, Yihuan Qiao, Jun Zhu, Jipeng Li
Frontiers in Oncology.2025;[Epub] CrossRef - Current Surgical Methods in Local Rectal Excision
Kristina Šemanjski, Karla Lužaić, Jure Brkić
Gastrointestinal Tumors.2024; : 1. CrossRef - Tailoring rectal cancer surgery: Surgical approaches and anatomical insights during deep pelvic dissection for optimal outcomes in low‐lying rectal cancer
Youn Young Park, Nam Kyu Kim
Annals of Gastroenterological Surgery.2024; 8(5): 761. CrossRef - A nomogram for predicting the overall survival in rectal cancer patients after total neoadjuvant therapy
Z. Liu, M. He, X. Wang
Techniques in Coloproctology.2024;[Epub] CrossRef - Impact of the laparoscopic approach, early closure and preoperative stimulation on outcomes of ileostomy closure after rectal resection
Andrea Norte, Carmen Martínez, Ana Pasalodos, Ivette Tort, Anna Sánchez, Pilar Hernández, Jesús Bollo, Eduard Maria Targarona
Cirugía Española (English Edition).2024; 102(11): 590. CrossRef - Impact of the laparoscopic approach, early closure and preoperative stimulation on outcomes of ileostomy closure after rectal resection
Andrea Norte, Carmen Martínez, Ana Pasalodos, Ivette Tort, Anna Sánchez, Pilar Hernández, Jesús Bollo, Eduard Maria Targarona
Cirugía Española.2024; 102(11): 590. CrossRef - Efficacy of Neoadjuvant Hypofractionated Chemoradiotherapy in Elderly Patients with Locally Advanced Rectal Cancer: A Single-Center Retrospective Analysis
Jae Seung Kim, Jaram Lee, Hyeung-min Park, Soo Young Lee, Chang Hyun Kim, Hyeong Rok Kim
Cancers.2024; 16(24): 4280. CrossRef - Unveiling the profound advantages of total neoadjuvant therapy in rectal cancer: a trailblazing exploration
Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim, Donghyoun Lee, Chinock Cheong
Annals of Surgical Treatment and Research.2023; 105(6): 341. CrossRef
- Reply to the Letter to the Editor ‘Circulating tumor DNA after definitive therapy for locally advanced rectal cancer’ by Drs Sorscher and Rocha Lima
Video
Video clip
- Laparoscopic right hemicolectomy with aortocaval lymphadenectomy, and pelvic peritoneum partial resection for ascending colon cancer
- Hannah Kim, An Na Seo, Soo Yeun Park
- Ann Coloproctol. 2023;39(3):283-286. Published online February 9, 2023
- DOI: https://doi.org/10.3393/ac.2022.00780.0111
- 4,720 View
- 122 Download
- 1 Web of Science
- 1 Citations
-
Abstract
PDFSupplementary Material
- The aim of this video is to present the procedural details of laparoscopic right hemicolectomy with aortocaval (infrarenal aortic bifurcation) lymphadenectomy, partial resection of the pelvic peritoneum (peritoneal carcinomatosis index, 3), and hyperthermic intraperitoneal chemotherapy in a patient who received neoadjuvant chemotherapy for stage IVc colorectal cancer. The total operation time was 290 minutes, and the patient was discharged on a postoperative day 13 without any complications. No postoperative complications occurred until postoperative day 60. The pathological stage of the tumor was determined to be T3N2bM1c. The pelvic peritoneal nodule was pathologically confirmed as a metastatic lesion. Among the 12 harvested aortocaval lymph nodes, 6 were metastatic lymph nodes. The minimally invasive approach was safe and feasible in this highly selected patient with colon cancer, aortocaval lymph nodes, and peritoneal metastases.
-
Citations
Citations to this article as recorded by- Clinical Effectiveness of Fluorescence Lymph Node Mapping Using ICG for Laparoscopic Right Hemicolectomy: A Prospective Case–Control Study
Gyung Mo Son, Mi Sook Yun, In Young Lee, Sun Bin Im, Kyung Hee Kim, Su Bum Park, Tae Un Kim, Dong-Hoon Shin, Armaan M. Nazir, Gi Won Ha
Cancers.2023; 15(20): 4927. CrossRef
- Clinical Effectiveness of Fluorescence Lymph Node Mapping Using ICG for Laparoscopic Right Hemicolectomy: A Prospective Case–Control Study
Case Report
Metastasis
- Peritoneal metastatic mixed adenoneuroendocrine carcinoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a case report
- Sungchul Lee, Euitae Kim, Dong-Guk Park
- Ann Coloproctol. 2024;40(Suppl 1):S18-S22. Published online November 21, 2022
- DOI: https://doi.org/10.3393/ac.2022.00339.0048
- 4,123 View
- 127 Download
- 1 Web of Science
- 1 Citations
-
Abstract
PDF
- A 61-year-old man presented with abdominal distension without any symptoms. On colonoscopy and computed tomography findings, it was clinically diagnosed as peritoneal metastasis of sigmoid colon cancer, and diagnostic laparoscopy was performed. Only the peritoneum was partially resected, and the pathology was signet ring cell carcinoma with predominantly local mucinous carcinoma component. However, the patient complained of persistent symptoms and, despite the progress of chemotherapy, the peritoneal dissemination worsened, and additional cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) was performed. Mixed adenoneuroendocrine carcinomas (MANECs) were reported in the appendix with perforated visceral peritoneum. After additional chemotherapy, the patient was discharged. Patients with advanced MANEC with peritoneal spreading may benefit from aggressive treatment by cytoreduction surgery with HIPEC, followed by intravenous chemotherapy.
-
Citations
Citations to this article as recorded by- Mixed neuroendocrine non-neuroendocrine neoplasms in gastroenteropancreatic tract
Sebastián Díaz-López, Jerónimo Jiménez-Castro, Carlos Enrique Robles-Barraza, Carlos Ayala-de Miguel, Manuel Chaves-Conde
World Journal of Gastrointestinal Oncology.2024; 16(4): 1166. CrossRef
- Mixed neuroendocrine non-neuroendocrine neoplasms in gastroenteropancreatic tract
Review
Malignant disease,Prognosis and adjuvant therapy,Colorectal cancer,Surgical technique
- Treatment for Peritoneal Metastasis of Patients With Colorectal Cancer
- Young Jin Kim, Chang Hyun Kim
- Ann Coloproctol. 2021;37(6):425-433. Published online December 22, 2021
- DOI: https://doi.org/10.3393/ac.2021.00920.0131
- 15,739 View
- 229 Download
- 28 Web of Science
- 29 Citations
-
Abstract
PDF
- From the perspective of survival outcomes, the cancer survival of colorectal cancer (CRC) in the whole stage has improved. Peritoneal metastasis (PM) is found in approximately 8% to 15% of patients with CRC, with a poorer prognosis than that associated with other sites of metastases. Randomized controlled trials and up-to-date meta-analyses provide firm evidence that cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) could significantly improve overall survival compared with systemic chemotherapy alone in selected patients with CRC-PM. Practical guidelines recommend that the management of CRC-PM should be led by a multidisciplinary team carried out in experienced centers and consider CRS plus HIPEC for selected patients. In this review, we aim to provide the latest results of land mark studies and an overview of recent insights with regard to the management of CRC-PM.
-
Citations
Citations to this article as recorded by- Molecular characterization of Pseudomyxoma peritonei with single-cell and bulk RNA sequencing
Ye Jin Ha, Seong-Hwan Park, Seon-Kyu Kim, Ka Hee Tak, Jeong-Hwan Kim, Chan Wook Kim, Yong Sik Yoon, Seon-Young Kim, Jong Lyul Lee
Scientific Data.2025;[Epub] CrossRef - Discovery of WEE1 Kinase Inhibitors with Potent Activity against Patient-Derived, Metastatic Colorectal Cancer Organoids
Joel L. Syphers, Josephine A. Wright, Shen Liu, Yi Sing Gee, Fan Gao, Ramesh Mudududdla, Da Qing Che, Aeson Chang, Erica K. Sloan, Vignesh Narasimhan, Alexander Heriot, Robert G. Ramsay, Rebekah de Nys, Tharindie N. Silva, Laura Vrbanac, Tarik Sammour, Ma
Journal of Medicinal Chemistry.2025; 68(8): 8065. CrossRef - A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for Appendiceal and Colorectal Adenocarcinoma with Peritoneal Metastasis
Justin M. Bader, Ava Ospina, Sean Liu, Biren Reddy, Princy Gupta, Ricarda Tomlin, Michael Cecchini, Raghav Sundar, Kiran Turaga
Annals of Surgical Oncology.2025; 32(8): 5784. CrossRef - Was there any change in surgical treatment for colorectal cancer during the COVID-19 pandemic?
Yeajin Moon, Seung Hun Lee, Seung Hyun Lee
Kosin Medical Journal.2025; 40(3): 207. CrossRef - Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus R0 resection for resectable colorectal cancer with peritoneal metastases and low peritoneal cancer index scores: a collaborative observational study from Korea and Japan
Daichi Kitaguchi, Eun Jung Park, Seung Hyuk Baik, Shoma Sasaki, Yuichiro Tsukada, Masaaki Ito
International Journal of Surgery.2024; 110(1): 45. CrossRef - CILP2 is a potential biomarker for the prediction and therapeutic target of peritoneal metastases in colorectal cancer
Ye Jin Ha, Seong-Hwan Park, Ka Hee Tak, Jong Lyul Lee, Chan Wook Kim, Jeong-Hwan Kim, Seon-Young Kim, Seon-Kyu Kim, Yong Sik Yoon
Scientific Reports.2024;[Epub] CrossRef - Comparison of EPIC Versus HIPEC in the Treatment of Colorectal Peritoneal Metastases and Appendix Tumors Using Inverse Probability of Treatment Weighting
Min Hye Jeong, Su Jin Kang, Soo Yeun Park, Sang Gyu Kwak, An Na Seo, Suehyun Park, Jun Seok Park, Hye Jin Kim, Gyu-Seog Choi
Annals of Surgical Oncology.2024; 31(10): 7111. CrossRef - Albumin Leakage Level during Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Associated with Major Complications
Hyun-Chang Kim, Dong Woo Han, Eun Jung Park, Yeon Hwa Hong, Young Song
Cancers.2024; 16(16): 2874. CrossRef - Inflammatory and nutritional markers in colorectal cancer: Implications for prognosis and treatment
Mesut Tez
World Journal of Clinical Oncology.2024; 15(10): 1264. CrossRef - Analgesic effects of combined transversus abdominis plane block and intramuscular electrical stimulation in patients undergoing cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy: a randomized controlled trial
Hyun-Chang Kim, Jinyoung Park, Jinyoung Oh, Minjae Kim, Eun Jung Park, Seung Hyuk Baik, Young Song
International Journal of Surgery.2023; 109(5): 1199. CrossRef - Do Laparoscopic Approaches Ensure Oncological Safety and Prognosis for Serosa-Exposed Colon Cancer? A Comparative Study against the Open Approach
Ji-Hyun Seo, In-Ja Park
Cancers.2023; 15(21): 5211. CrossRef - Fluorescence-guided colorectal surgery: applications, clinical results, and protocols
Jin-Min Jung, In Ja Park, Eun Jung Park, Gyung Mo Son
Annals of Surgical Treatment and Research.2023; 105(5): 252. CrossRef - Improving nanochemoimmunotherapy efficacy by boosting “eat-me” signaling and downregulating “don't-eat-me” signaling with Ganoderma lucidum polysaccharide-based drug delivery
Guibin Pang, Siqi Wei, Jian Zhao, Fu-Jun Wang
Journal of Materials Chemistry B.2023; 11(48): 11562. CrossRef - Effect of Intraperitoneal Chemotherapy with Regorafenib on IL-6 and TNF-α Levels and Peritoneal Cytology: Experimental Study in Rats with Colorectal Peritoneal Carcinomatosis
Stefanos Bitsianis, Ioannis Mantzoros, Elissavet Anestiadou, Panagiotis Christidis, Christos Chatzakis, Konstantinos Zapsalis, Savvas Symeonidis, Georgios Ntampakis, Kalliopi Domvri, Anastasia Tsakona, Chryssa Bekiari, Orestis Ioannidis, Stamatios Aggelop
Journal of Clinical Medicine.2023; 12(23): 7267. CrossRef - Recurrence Patterns and Risk Factors after Curative Resection for Colorectal Cancer: Insights for Postoperative Surveillance Strategies
Hyo Seon Ryu, Jin Kim, Ye Ryung Park, Eun Hae Cho, Jeong Min Choo, Ji-Seon Kim, Se-Jin Baek, Jung-Myun Kwak
Cancers.2023; 15(24): 5791. CrossRef - Advances in the Treatment of Colorectal Cancer with Peritoneal Metastases: A Focus on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Youngbae Jeon, Eun Jung Park
The Ewha Medical Journal.2023;[Epub] CrossRef - Influence of the COVID-19 Pandemic on the Treatment Patterns and Outcomes of Colorectal Cancer
In Ja Park
The Ewha Medical Journal.2023;[Epub] CrossRef - The Onset of In-Vivo Dehydration in Gas -Based Intraperitoneal Hyperthermia and Its Cytotoxic Effects on Colon Cancer Cells
Agata Diakun, Tanja Khosrawipour, Agata Mikolajczyk-Martinez, Jakub Nicpoń, Zdzisław Kiełbowicz, Przemysław Prządka, Bartłomiej Liszka, Wojciech Kielan, Kacper Zielinski, Pawel Migdal, Hien Lau, Shiri Li, Veria Khosrawipour
Frontiers in Oncology.2022;[Epub] CrossRef - Patients with Metachronous Peritoneal Metastatic Mucinous Colorectal Adenocarcinoma Benefit More from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) than Their Synchronous Counterparts
Zoltan Herold, Miklos Acs, Attila Marcell Szasz, Katalin Olasz, Jana Hussong, Max Mayr, Magdolna Dank, Pompiliu Piso
Cancers.2022; 14(16): 3978. CrossRef - ASO Author Reflections: Is it Correct to Use 5% Dextrose Solution as a Carrier Fluid for Oxaliplatin-based HIPEC?
Eun Jung Park, Sung-Joo Hwang, Seung Hyuk Baik
Annals of Surgical Oncology.2022; 29(13): 8593. CrossRef - Pharmacologic Effects of Oxaliplatin Instability in Chloride-Containing Carrier Fluids on the Hyperthermic Intraperitoneal Chemotherapy to Treat Colorectal Cancer In Vitro and In Vivo
Eun Jung Park, Junhyun Ahn, Sharif Md Abuzar, Kyung Su Park, Sung-Joo Hwang, Seung Hyuk Baik
Annals of Surgical Oncology.2022; 29(13): 8583. CrossRef - Benign multicystic mesothelioma of appendiceal origin treated by hyperthermic intraperitoneal chemotherapy: A case report
Suk Jun Lee, Ji Hae Nahm, Jeonghyun Kang, Seung Hyuk Baik, Eun Jung Park
International Journal of Surgery Case Reports.2022; 99: 107665. CrossRef - Molecular analyses of peritoneal metastasis from colorectal cancer
Chang Hyun Kim
Journal of the Korean Medical Association.2022; 65(9): 586. CrossRef - Surgical treatment for metastatic colorectal cancer
Eun Jung Park, Seung Hyuk Baik
Journal of the Korean Medical Association.2022; 65(9): 568. CrossRef - Direction of diagnosis and treatment improvement in colorectal cancer
In Ja Park
Journal of the Korean Medical Association.2022; 65(9): 540. CrossRef - Recent Advance in the Surgical Treatment of Metastatic Colorectal Cancer-An English Version
Eun Jung Park, Seung Hyuk Baik
Journal of the Anus, Rectum and Colon.2022; 6(4): 213. CrossRef - Molecular Analyses in Peritoneal Metastasis from Colorectal Cancer: A Review-An English Version
Chang Hyun Kim
Journal of the Anus, Rectum and Colon.2022; 6(4): 197. CrossRef - Update on Diagnosis and Treatment of Colorectal
Cancer
Chan Wook Kim
The Ewha Medical Journal.2022;[Epub] CrossRef - It Is a Pleasure to Announce the Issue Titled “Master Class 2021” in Annals of Coloproctology
In Ja Park
Annals of Coloproctology.2021; 37(6): 349. CrossRef
- Molecular characterization of Pseudomyxoma peritonei with single-cell and bulk RNA sequencing
Original Articles
Malignant disease,Rectal cancer, Prognosis and adjuvant therapy,Colorectal cancer
- Effect of Adjuvant Chemotherapy on Elderly Stage II High-Risk Colorectal Cancer Patients
- Yujin Lee, Inseok Park, Hyunjin Cho, Geumhee Gwak, Keunho Yang, Byung-Noe Bae
- Ann Coloproctol. 2021;37(5):298-305. Published online July 6, 2021
- DOI: https://doi.org/10.3393/ac.2020.00829.0118
- 5,851 View
- 100 Download
- 16 Web of Science
- 19 Citations
-
Abstract
PDF
- Purpose
Adjuvant chemotherapy (AC) is recommended for patients with stage II colorectal cancer with adverse features. However, the effect of adjuvant treatment in elderly patients with high-risk stage II colorectal cancer remains controversial. This study aimed to investigate the oncologic outcomes in elderly high-risk stage II colorectal cancer patients who underwent curative resection with or without AC.
Methods
Patients aged over 70 years having stage II colorectal adenocarcinoma with at least 1 adverse feature who underwent radical surgery between 2008 and 2017 at a single center were included. We compared recurrence-free survival (RFS) and overall survival (OS) between patients who received more than 80% of the planned AC cycle (the AC+ group) and those who did not receive it (the AC− group).
Results
The AC+ and AC– group contained 46 patients and 50 patients, respectively. The log-rank test revealed no significant intergroup differences in RFS (P = 0.083) and OS (P = 0.122). In the subgroup of 27 patients with more than 2 adverse features, the AC+ group (n = 16) showed better RFS (P = 0.006) and OS (P = 0.025) than the AC− group. In this subgroup, AC was the only significant factor affecting RFS in the multivariate analysis (P = 0.023). AC was significantly associated with OS (P = 0.033) in the univariate analysis, but not in the multivariate analysis (P = 0.332).
Conclusion
Among elderly patients with stage II high-risk colorectal cancer, the AC+ group did not show better RFS or OS than the AC− group. However, selected patients with more than 2 adverse features might benefit from AC. -
Citations
Citations to this article as recorded by- Tumor aggression-defense index–a novel indicator to predicts recurrence and survival in stage II-III colorectal cancer
Tong Wu, Lin Fang, Yuli Ruan, Mengde Shi, Dan Su, Yue Ma, Ming Ma, Bojun Wang, Yuanyu Liao, Shuling Han, Xiaolin Lu, Chunhui Zhang, Chao Liu, Yanqiao Zhang
Journal of Translational Medicine.2025;[Epub] CrossRef - Oncologic outcomes and associated factors of colon cancer patients aged 70 years and older
Byeo Lee Lim, In Ja Park, Jun-Soo Ro, Young Il Kim, Seok-Byung Lim, Chang Sik Yu
Annals of Coloproctology.2025; 41(3): 198. CrossRef - Predicting venous thromboembolism and determining appropriate prophylaxis in elderly patients undergoing colorectal cancer surgery with Enhanced Recovery After Surgery (ERAS) using the adjusted Caprini score
Young Sun Choi, Hyung Jin Cho, Chul Seung Lee, Dong Geun Lee, Choon Sik Chung, Gwan Cheol Lee, Dong Woo Kang, Jeong Sub Kim, Tae Gyu Kim
Annals of Coloproctology.2025; 41(4): 279. CrossRef - A Prognostic Model Based on the Log Odds Ratio of Positive Lymph Nodes Predicts Prognosis of Patients with Rectal Cancer
Jian Li, Yu zhou Yang, Peng Xu, Cheng Zhang
Journal of Gastrointestinal Cancer.2024; 55(3): 1111. CrossRef - Complete Obstruction, a Real Risk Factor: A Comprehensive Study on Obstruction in Stage IIA Colon Cancer With Propensity Score Matching Analysis
Soo Young Oh, Chan Wook Kim, Seonok Kim, Min Hyun Kim, Young Il Kim, Jong Lyul Lee, Yong Sik Yoon, In Ja Park, Seok-Byung Lim, Chang Sik Yu
Clinical Colorectal Cancer.2024; 23(2): 135. CrossRef - Clinical implication of tissue carcinoembryonic antigen expression in association with serum carcinoembryonic antigen in colorectal cancer
Abdulmohsin Fawzi Aldilaijan, Young Il Kim, Chan Wook Kim, Yong Sik Yoon, In Ja Park, Seok-Byung Lim, Jihun Kim, Jun-Soo Ro, Jin Cheon Kim
Scientific Reports.2023;[Epub] CrossRef - Advances in the Treatment of Colorectal Cancer with Peritoneal Metastases: A Focus on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Youngbae Jeon, Eun Jung Park
The Ewha Medical Journal.2023;[Epub] CrossRef - Oncologic outcomes in elderly patients who underwent hysterectomy for endometrial cancer: a multi-institutional survey in Kinki District, Japan
Tomohito Tanaka, Suguru Yamashita, Haruo Kuroboshi, Junya Kamibayashi, Atsushi Sugiura, Kaori Yoriki, Taisuke Mori, Kazuharu Tanaka, Aiko Nagashima, Michihide Maeda, Shoji Kamiura, Yukako Mizuno, Noriko Ohtake, Tomoyuki Ichimura, Taiki Kikuchi, Yuri Nobut
International Journal of Clinical Oncology.2022; 27(6): 1084. CrossRef - Does adjuvant chemotherapy improve outcomes in elderly patients with colorectal cancer? A systematic review and meta-analysis of real-world studies
Jianbing Chen, Chengda Zhang, Yajuan Wu
Expert Review of Gastroenterology & Hepatology.2022; 16(4): 383. CrossRef - Risk factors for recurrence in elderly patients with stage II colorectal cancer: a multicenter retrospective study
Takuki Yagyu, Manabu Yamamoto, Akimitsu Tanio, Kazushi Hara, Ken Sugezawa, Chihiro Uejima, Kyoichi Kihara, Shigeru Tatebe, Yasuro Kurisu, Shunsuke Shibata, Toshio Yamamoto, Hiroshi Nishie, Setsujo Shiota, Hiroaki Saito, Takuji Naka, Kenji Sugamura, Kuniyu
BMC Cancer.2022;[Epub] CrossRef - Effects of the Enhanced Recovery After Surgery (ERAS) Program for Colorectal Cancer Patients Undergoing Laparoscopic Surgery
Jeongwon Yeom, Hee-Sook Lim
Clinical Nutrition Research.2022; 11(2): 75. CrossRef - The Prognostic Reliability of Lymphovascular Invasion for Patients with T3N0 Colorectal Cancer in Adjuvant Chemotherapy Decision Making
Hayoung Lee, Seung-Yeon Yoo, In Ja Park, Seung-Mo Hong, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
Cancers.2022; 14(12): 2833. CrossRef - Is the oncological impact of vascular invasion more important in right colon cancer?
Gyung Mo Son
Journal of Minimally Invasive Surgery.2022; 25(2): 49. CrossRef - Molecular analyses of peritoneal metastasis from colorectal cancer
Chang Hyun Kim
Journal of the Korean Medical Association.2022; 65(9): 586. CrossRef - Epidemiology, risk factors, and prevention of colorectal cancer
Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim
Journal of the Korean Medical Association.2022; 65(9): 549. CrossRef - Molecular Analyses in Peritoneal Metastasis from Colorectal Cancer: A Review-An English Version
Chang Hyun Kim
Journal of the Anus, Rectum and Colon.2022; 6(4): 197. CrossRef - Epidemiology, Risk Factors, and Prevention of Colorectal Cancer-An English Version
Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim
Journal of the Anus, Rectum and Colon.2022; 6(4): 231. CrossRef - Adjuvant chemotherapy benefits on patients with elevated carcinoembryonic antigen in stage IIA colon cancer: a SEER-based analysis
Huabin Zhou, Songsheng Wang, Zhai Cai, Enming Qiu, Qianyun Chen, Xi Rao, Shuai Han, Zhou Li
International Journal of Colorectal Disease.2022; 37(12): 2481. CrossRef - Elderly High-Risk Stage II Colorectal Cancer Patients: Candidates for Improving Outcome?
Min Ki Kim
Annals of Coloproctology.2021; 37(5): 267. CrossRef
- Tumor aggression-defense index–a novel indicator to predicts recurrence and survival in stage II-III colorectal cancer
Malignant disease,Prognosis and adjuvant therapy,Colorectal cancer
- Prognostic Factors Affecting Disease-Free Survival and Overall Survival in T4 Colon Cancer
- Taeyeong Eom, Yujin Lee, Jungbin Kim, Inseok Park, Geumhee Gwak, Hyunjin Cho, Keunho Yang, Kiwhan Kim, Byung-Noe Bae
- Ann Coloproctol. 2021;37(4):259-265. Published online June 24, 2021
- DOI: https://doi.org/10.3393/ac.2020.00759.0108
- Correction in: Ann Coloproctol 2023;39(5):444
- 7,627 View
- 109 Download
- 19 Web of Science
- 19 Citations
-
Abstract
PDF
- Purpose
It is known that as the T stage of a carcinoma progresses, the prognosis becomes poorer. However, there are few studies about factors that affect the prognosis of T4 advanced colon cancer. This study aimed to identify the prognostic factors associated with disease-free survival (DFS) and overall survival (OS) in T4 colon cancer.
Methods
Patients diagnosed with stage T4 on histopathology after undergoing curative surgery for colon cancer between March 2009 and March 2018 were retrospectively analyzed for factors related to postoperative survival. Primary outcomes were DFS and OS.
Results
Eighty-two patients were included in the study. DFS and OS of the pathologic (p) T4b group were not inferior to that of the pT4a group. Multivariate analysis showed that differentiation (hazard ratio [HR], 4.994; P = 0.005), and laparoscopic surgery (HR, 0.323; P = 0.008) were significant prognostic factors for DFS, while differentiation (HR, 7.904; P ≤ 0.001) and chemotherapy (HR, 0.344; P = 0.038) were significant prognostic factors for OS.
Conclusion
Tumor differentiation, laparoscopic surgery, and adjuvant chemotherapy were found to be significant prognostic factors in patients with T4 colon cancer. Adjuvant chemotherapy and curative resections by laparoscopy might improve the prognosis in these patients. -
Citations
Citations to this article as recorded by- Tailored-surgery for locally advanced colon cancer based on 3D mathematical reconstruction surgical planner: Observational comparative non-randomized study
Sebastián Jerí-McFarlane, Álvaro García-Granero, Marco Antonio Martínez-Ortega, Isabel Amengual-Antich, Ángela Rodríguez Robayo, Margarita Gamundí-Cuesta, Francisco Xavier González-Argenté
European Journal of Surgical Oncology.2025; 51(2): 109584. CrossRef - Prognostic Factors of Postoperative Mortality in Patients with Complicated Right Colon Cancer
Raul Mihailov, Corina Dima, Bianca Georgiana Constantin, Florentin Dimofte, Mihaela Craescu, Lavinia Moroianu, Laura Iuliana Candussi, Virginia Lutenco, Oana Mariana Mihailov, Valerii Lutenco
Life.2025; 15(3): 350. CrossRef - The impact of sarcopenic obesity on the prevalence and prognosis of non-metastatic colorectal cancer: A systematic review and meta-analysis
Wanping Wang, Fang Fang, Tianxiu Wang, Xinyi Chen, Lu Zhao, Chunmei Wang, Yujia Tang, Qin Li, Dong Tang, Jingqiu Zhang
Clinical Nutrition ESPEN.2025; 69: 492. CrossRef - Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus R0 resection for resectable colorectal cancer with peritoneal metastases and low peritoneal cancer index scores: a collaborative observational study from Korea and Japan
Daichi Kitaguchi, Eun Jung Park, Seung Hyuk Baik, Shoma Sasaki, Yuichiro Tsukada, Masaaki Ito
International Journal of Surgery.2024; 110(1): 45. CrossRef - Cytotoxicity of Salvigenin from Asterohyptis stellulata in Combination with Clinical Drugs Against Colorectal Cancer
Briand André Rojas-Castaño, Adriana C. Hernández-Rojas, Rogelio Pereda-Miranda, Mabel Fragoso-Serrano
Revista Brasileira de Farmacognosia.2024; 34(5): 1172. CrossRef - Sorbate metal complexes as newer antibacterial, antibiofilm, and anticancer compounds
Amira I. Abousaty, Fifi M. Reda, Wessam A. Hassanin, Walaa M. Felifel, Walaa H. El-Shwiniy, Heba M. R. M. Selim, Mahmoud M. Bendary
BMC Microbiology.2024;[Epub] CrossRef - The Association Between Surgical Site Infection and Prognosis of T4 Colorectal Cancer
Takuya Koike, Masaya Mukai, Kyoko Kishima, Daiki Yokoyama, Sayuri Hasegawa, Lin Fung Chan, Hideki Izumi, Kazutake Okada, Tomoko Sugiyama, Takuma Tajiri
Cureus.2024;[Epub] CrossRef - Utilizing stimuli-responsive nanoparticles to deliver and enhance the anti-tumor effects of bilirubin
Elaheh Mirhadi, Alexandra E. Butler, Prashant Kesharwani, Amirhossein Sahebkar
Biotechnology Advances.2024; 77: 108469. CrossRef - Can clinicopathologic high-risk features in T3N0 colon cancer be reliable prognostic factors?
Hyun Gu Lee, Young IL Kim, In Ja Park, Seok-Byung Lim, Chang Sik Yu
Annals of Surgical Treatment and Research.2023; 104(2): 109. CrossRef - Clinical implication of tissue carcinoembryonic antigen expression in association with serum carcinoembryonic antigen in colorectal cancer
Abdulmohsin Fawzi Aldilaijan, Young Il Kim, Chan Wook Kim, Yong Sik Yoon, In Ja Park, Seok-Byung Lim, Jihun Kim, Jun-Soo Ro, Jin Cheon Kim
Scientific Reports.2023;[Epub] CrossRef - Do Laparoscopic Approaches Ensure Oncological Safety and Prognosis for Serosa-Exposed Colon Cancer? A Comparative Study against the Open Approach
Ji-Hyun Seo, In-Ja Park
Cancers.2023; 15(21): 5211. CrossRef - Erratum to “Prognostic factors affecting disease-free survival and overall survival in T4 colon cancer”
Annals of Coloproctology.2023; 39(5): 444. CrossRef - Inflammatory Response Markers as Predictors of Colorectal Cancer Prognosis
Minsung Kim, Il Tae Son, Bo Young Oh
The Ewha Medical Journal.2023;[Epub] CrossRef - The Prognostic Reliability of Lymphovascular Invasion for Patients with T3N0 Colorectal Cancer in Adjuvant Chemotherapy Decision Making
Hayoung Lee, Seung-Yeon Yoo, In Ja Park, Seung-Mo Hong, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
Cancers.2022; 14(12): 2833. CrossRef - Molecular analyses of peritoneal metastasis from colorectal cancer
Chang Hyun Kim
Journal of the Korean Medical Association.2022; 65(9): 586. CrossRef - Molecular Analyses in Peritoneal Metastasis from Colorectal Cancer: A Review-An English Version
Chang Hyun Kim
Journal of the Anus, Rectum and Colon.2022; 6(4): 197. CrossRef - Impact on inadequate lymph node harvest on survival in T4N0 colorectal cancer: A would-be medical center experience in Taiwan
Yi-Kai Kao, Hsin-Pao Chen, Kuang-Wen Liu, Ling-Chiao Song, Yi-Chieh Chen, Yu-Chun Lin, Chih-I Chen
Medicine.2022; 101(52): e32497. CrossRef - Prognostic risk factors for pT4 colon cancer: A retrospective cohort study
Tsutomu Kumamoto, Shigeki Yamaguchi, Ryosuke Nakagawa, Yoji Nagashima, Fumi Maeda, Kimitaka Tani, Hiroka Kondo, Kurodo Koshino, Yuka Kaneko, Yoshiko Bamba, Shimpei Ogawa, Yuji Inoue, Michio Itabashi
Oncology Letters.2022;[Epub] CrossRef - Antiproliferative and palliative activity of flavonoids in colorectal cancer
Javier Fernández, Blanca Silván, Rodrigo Entrialgo-Cadierno, Claudio J. Villar, Raffaele Capasso, José Antonio Uranga, Felipe Lombó, Raquel Abalo
Biomedicine & Pharmacotherapy.2021; 143: 112241. CrossRef
- Tailored-surgery for locally advanced colon cancer based on 3D mathematical reconstruction surgical planner: Observational comparative non-randomized study
Malignant disease,Prognosis and adjuvant therapy,Colorectal cancer,Biomarker & risk factor
- Prognostic Factor and Survival Benefit of Adjuvant Chemotherapy in Stage IIA Colon Cancer
- Mok-Won Lee, Jin-Su Kim, Ji-Yeon Kim, Kyung-ha Lee
- Ann Coloproctol. 2021;37(1):35-43. Published online September 18, 2020
- DOI: https://doi.org/10.3393/ac.2020.09.03
- 5,799 View
- 136 Download
- 10 Web of Science
- 8 Citations
-
Abstract
PDF
- Purpose
There is no clear evidence of the benefit of adjuvant chemotherapy (AC) in stage IIA colon cancer. Therefore, we aimed to evaluate the prognostic factors and survival benefit of AC in this disease.
Methods
A retrospective data collection for patients who underwent radical surgery for colon cancer between January 2008 and December 2015 was undertaken. The cohort was divided into the no-AC and AC groups.
Results
We included 227 patients with stage IIA colon cancer in our study cohort, including 67 and 160 patients in the no-AC and AC groups, respectively. The number of retrieved lymph nodes and the presence of tumor complications as obstruction or perforation were independent risk factors for survival. In the no-AC group, there was a significant difference in survival according to the number of retrieved lymph nodes. In the AC group, there were significant differences in survival according to sidedness and preoperative carcinoembryonic antigen (CEA). There was no significant difference in survival between the no-AC and the AC groups.
Conclusion
The number of retrieved lymph nodes and the presence of tumor complications were prognostic factors for stage IIA colon cancer but lymphovascular and perineural invasion were not. Sidedness and preoperative CEA could be used as factors to predict the benefit of adjuvant chemotherapy. Currently, it is believed that there is no benefit of AC for stage IIA colon cancer. Further studies are needed to determine the survival benefit of adjuvant chemotherapy in stage IIA colon cancer. -
Citations
Citations to this article as recorded by- Can clinicopathologic high-risk features in T3N0 colon cancer be reliable prognostic factors?
Hyun Gu Lee, Young IL Kim, In Ja Park, Seok-Byung Lim, Chang Sik Yu
Annals of Surgical Treatment and Research.2023; 104(2): 109. CrossRef - Clinical Effectiveness of Fluorescence Lymph Node Mapping Using ICG for Laparoscopic Right Hemicolectomy: A Prospective Case–Control Study
Gyung Mo Son, Mi Sook Yun, In Young Lee, Sun Bin Im, Kyung Hee Kim, Su Bum Park, Tae Un Kim, Dong-Hoon Shin, Armaan M. Nazir, Gi Won Ha
Cancers.2023; 15(20): 4927. CrossRef - Impact of Postoperative Naples Prognostic Score to Predict Survival in Patients with Stage II–III Colorectal Cancer
Su Hyeong Park, Hye Seung Woo, In Kyung Hong, Eun Jung Park
Cancers.2023; 15(20): 5098. CrossRef - The Prognostic Reliability of Lymphovascular Invasion for Patients with T3N0 Colorectal Cancer in Adjuvant Chemotherapy Decision Making
Hayoung Lee, Seung-Yeon Yoo, In Ja Park, Seung-Mo Hong, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
Cancers.2022; 14(12): 2833. CrossRef - Molecular Analyses in Peritoneal Metastasis from Colorectal Cancer: A Review-An English Version
Chang Hyun Kim
Journal of the Anus, Rectum and Colon.2022; 6(4): 197. CrossRef - Adjuvant chemotherapy benefits on patients with elevated carcinoembryonic antigen in stage IIA colon cancer: a SEER-based analysis
Huabin Zhou, Songsheng Wang, Zhai Cai, Enming Qiu, Qianyun Chen, Xi Rao, Shuai Han, Zhou Li
International Journal of Colorectal Disease.2022; 37(12): 2481. CrossRef - Molecular analyses of peritoneal metastasis from colorectal cancer
Chang Hyun Kim
Journal of the Korean Medical Association.2022; 65(9): 586. CrossRef - Direction of diagnosis and treatment improvement in colorectal cancer
In Ja Park
Journal of the Korean Medical Association.2022; 65(9): 540. CrossRef
- Can clinicopathologic high-risk features in T3N0 colon cancer be reliable prognostic factors?
Malignant disease
- Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Mitomycin C Used for Colorectal Peritoneal Carcinomatosis
- Seung Jae Roh, Sung Chan Park, Jaehee Choi, Joon Sang Lee, Dong Woon Lee, Chang Won Hong, Kyung Su Han, Hyoung Chul Park, Dae Kyung Sohn, Jae Hwan Oh
- Ann Coloproctol. 2020;36(1):22-29. Published online February 29, 2020
- DOI: https://doi.org/10.3393/ac.2019.04.30
- 7,652 View
- 177 Download
- 23 Web of Science
- 22 Citations
-
Abstract
PDF
- Purpose
This study aimed to assess the evaluation of clinical outcomes and consequences of complications after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for the peritoneal carcinomatosis (PC) from colorectal cancer.
Methods
A total 26 patients underwent CRS and HIPEC for PC from colorectal cancer between March 2009 and April 2018. All the patients underwent CRS with the purpose of complete or near-complete cytoreduction. Intraoperative HIPEC was performed simultaneously after the CRS. Mitomycin C was used as chemotherapeutic agent for HIPEC.
Results
Median disease-free survival was 27.8 months (range, 13.4–42.2 months). Median overall survival was 56.0 months (range, 28.6–83.5 months). The mean peritoneal cancer index (PCI) was 8.73 ± 5.54. The distributions thereof were as follows: PCI <10, 69.23%; PCI 10–19, 23.08%; and PCI ≥20, 7.69%. The completeness of cytoreduction was 96.2% of patients showed CC-0, with 3.8% achieved CC-1. The mean operation time was 8.5 hours, and the mean postoperative hospital stay was 21.6 days. The overall rate of early postoperative complications was 88.5%; the rate of late complications was 34.6%. In the early period, most complications were grades I–II complications (65.4%), compared to grades III–V (23.1%). All late complications, occurring in 7.7% of patients, were grades III–V. There was no treatment-related mortality.
Conclusion
Although the complication rate was approximately 88%, but the rate of severe complication rate was low. In selective patients with peritoneal recurrence, more aggressive strategies for management, such as CRS with HIPEC, were able to be considered under the acceptable general condition and life-expectancy. -
Citations
Citations to this article as recorded by- Harnessing Hyperthermia: Molecular, Cellular, and Immunological Insights for Enhanced Anticancer Therapies
Szilvia Lukácsi, Gyöngyi Munkácsy, Balázs Győrffy
Integrative Cancer Therapies.2024;[Epub] CrossRef - Diagnostic and Prognostic Potential of Long Non-Coding RNAs GAS5, MALAT1, CCAT2, HOTAIR and H19 in Colorectal Cancer Cases with Peritoneal Metastases
Alpaslan Tanoglu, Esra Guzel Tanoglu, Erdal Polat, Muhammed Fevzi Esen, Nagehan Ozdemir Barisik
Brazilian Archives of Biology and Technology.2024;[Epub] CrossRef - Albumin Leakage Level during Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Associated with Major Complications
Hyun-Chang Kim, Dong Woo Han, Eun Jung Park, Yeon Hwa Hong, Young Song
Cancers.2024; 16(16): 2874. CrossRef - Challenges following CRS and HIPEC surgery in cancer patients with peritoneal metastasis: a comprehensive review of clinical outcomes
Mehdi Karimi, Niyousha Shirsalimi, Eshagh Sedighi
Frontiers in Surgery.2024;[Epub] CrossRef - Analgesic effects of combined transversus abdominis plane block and intramuscular electrical stimulation in patients undergoing cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy: a randomized controlled trial
Hyun-Chang Kim, Jinyoung Park, Jinyoung Oh, Minjae Kim, Eun Jung Park, Seung Hyuk Baik, Young Song
International Journal of Surgery.2023; 109(5): 1199. CrossRef - The Design of an Automatic Temperature Compensation System through Smart Heat Comparison/Judgment and Control for Stable Thermal Treatment in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Surgery
Kicheol Yoon, Sangyun Lee, Tae-Hyeon Lee, Kwang Gi Kim
Sensors.2023; 23(15): 6722. CrossRef - Epidemiology of psychiatric disorders following cytoreductive surgeries plus hyperthermic intraperitoneal chemotherapy: a prospective cohort analysis
Guillaume Economos, Vahan Kepenekian, Cécile Barbaret, Laurent Villeneuve, Julie Haesebaert, Olivier Glehen
Scientific Reports.2023;[Epub] CrossRef - Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis
Suk Jun Lee, Youngbae Jeon, Hae Won Lee, Jeonghyun Kang, Seung Hyuk Baik, Eun Jung Park
Annals of Surgical Oncology.2022; 29(3): 2077. CrossRef - What is the ideal management of Krukenberg syndrome?
Carolina Arró Ortiz, Darío Ramallo, Nicolás Guerrini
Journal of Surgical Case Reports.2022;[Epub] CrossRef - ASO Author Reflections: Is it Correct to Use 5% Dextrose Solution as a Carrier Fluid for Oxaliplatin-based HIPEC?
Eun Jung Park, Sung-Joo Hwang, Seung Hyuk Baik
Annals of Surgical Oncology.2022; 29(13): 8593. CrossRef - Pharmacologic Effects of Oxaliplatin Instability in Chloride-Containing Carrier Fluids on the Hyperthermic Intraperitoneal Chemotherapy to Treat Colorectal Cancer In Vitro and In Vivo
Eun Jung Park, Junhyun Ahn, Sharif Md Abuzar, Kyung Su Park, Sung-Joo Hwang, Seung Hyuk Baik
Annals of Surgical Oncology.2022; 29(13): 8583. CrossRef - Benign multicystic mesothelioma of appendiceal origin treated by hyperthermic intraperitoneal chemotherapy: A case report
Suk Jun Lee, Ji Hae Nahm, Jeonghyun Kang, Seung Hyuk Baik, Eun Jung Park
International Journal of Surgery Case Reports.2022; 99: 107665. CrossRef - Molecular analyses of peritoneal metastasis from colorectal cancer
Chang Hyun Kim
Journal of the Korean Medical Association.2022; 65(9): 586. CrossRef - Surgical treatment for metastatic colorectal cancer
Eun Jung Park, Seung Hyuk Baik
Journal of the Korean Medical Association.2022; 65(9): 568. CrossRef - Molecular Analyses in Peritoneal Metastasis from Colorectal Cancer: A Review-An English Version
Chang Hyun Kim
Journal of the Anus, Rectum and Colon.2022; 6(4): 197. CrossRef - Recent Advance in the Surgical Treatment of Metastatic Colorectal Cancer-An English Version
Eun Jung Park, Seung Hyuk Baik
Journal of the Anus, Rectum and Colon.2022; 6(4): 213. CrossRef - Update on Diagnosis and Treatment of Colorectal
Cancer
Chan Wook Kim
The Ewha Medical Journal.2022;[Epub] CrossRef - Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery for Colorectal Peritoneal Carcinomatosis Patients: A Review
Sarah S Alhumaidan, Abeer M Alharbi, Ayesha Farhana Syeda, Fatimah A Alghaidani, Manal M Almutairi, Nourah A Alharbi, Reham K Alenezi
Cureus.2022;[Epub] CrossRef - Hyperthermia generated by magnetic nanoparticles for effective treatment of disseminated peritoneal cancer in an orthotopic nude-mouse model
Yuki Matsumi, Tetsuya Kagawa, Shuya Yano, Hiroshi Tazawa, Kunitoshi Shigeyasu, Sho Takeda, Toshiaki Ohara, Hiromichi Aono, Robert M. Hoffman, Toshiyoshi Fujiwara, Hiroyuki Kishimoto
Cell Cycle.2021; 20(12): 1122. CrossRef - Treatment for Peritoneal Metastasis of Patients With Colorectal Cancer
Young Jin Kim, Chang Hyun Kim
Annals of Coloproctology.2021; 37(6): 425. CrossRef - Hyperthermic Intrathoracic Chemoperfusion for Malignant Pleural Mesothelioma: Systematic Review and Meta-Analysis
Tommi Järvinen, Juuso Paajanen, Ilkka Ilonen, Jari Räsänen
Cancers.2021; 13(14): 3637. CrossRef - Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies
Xubing Zhang, Qingbin Wu, Mingtian Wei, Xiangbing Deng, Chaoyang Gu, Ziqiang Wang
International Journal of Colorectal Disease.2020; 35(10): 1831. CrossRef
- Harnessing Hyperthermia: Molecular, Cellular, and Immunological Insights for Enhanced Anticancer Therapies
Malignant disease, Rectal cancer,Prognosis and adjuvant therapy
- Effect of Age on Laparoscopic Surgery and Postoperative Chemotherapy in Elderly Patients With Colorectal Cancer
- Hyun Hee Kim, Myong Hoon Ihn, Yun Hee Lee, Jihyoun Lee, Sangchul Yun, Sung Woo Cho
- Ann Coloproctol. 2020;36(4):229-242. Published online January 31, 2020
- DOI: https://doi.org/10.3393/ac.2019.10.03
- 5,813 View
- 104 Download
- 11 Web of Science
- 12 Citations
-
Abstract
PDFSupplementary Material
- Purpose
We aimed to evaluate the postoperative complications of laparoscopic colorectal cancer (CRC) surgery and the adverse events of postoperative chemotherapy in elderly patients compared to younger patients and to identify the factors influencing the termination of postoperative chemotherapy.
Methods
Between June 2015 and May 2018, 188 patients with CRC underwent laparoscopic surgery with curative intent. Patients aged ≥ 70 were defined as elderly. Postoperative complications and adverse events of chemotherapy were assessed by using the Clavien-Dindo classification and the Common Terminology Criteria for Adverse Events, respectively. The clinicopathological factors were analyzed retrospectively.
Results
Seventy-eight patients were considered elderly with a mean age of 77.5 ± 5.5 years. Overall postoperative complications occurred in 68 patients (36.2%). Age and primary tumor location were independent predictors of overall postoperative complications. Smoking history was the only independent predictor of major postoperative complications. Of 113 patients who were recommended postoperative chemotherapy, 90 patients (79.6%) received postoperative chemotherapy. Overall adverse events occurred in 40 patients (44.4%). The American Society of Anesthesiologists physical status classification and chemotherapy regimen were significantly associated with overall adverse events. The chemotherapy regimen was the only factor significantly associated with severe adverse events. Of 90 patients, postoperative chemotherapy could not be completed in 11 (12.2%). Age was the only factor significantly associated with stopping postoperative chemotherapy (P = 0.003).
Conclusion
This study shows that laparoscopic CRC surgery and postoperative chemotherapy were feasible in elderly patients. Further efforts are needed to ensure that elderly patients have the opportunity to make informed decisions regarding postoperative chemotherapy. -
Citations
Citations to this article as recorded by- Outcome of robotic colon surgery in older patients with colon cancer
Ellen Van Eetvelde, Manu Verweirder, Lore Decoster, Daniel Jacobs-Tulleneers-Thevissen
Journal of Geriatric Oncology.2025; 16(3): 102205. CrossRef - Survival Benefits of Postoperative Chemotherapy in Patients With Colorectal Mucinous Adenocarcinoma: An Analysis Utilizing Propensity Score Matching From the Surveillance, Epidemiology, and End Results Database
Jun Rong, Wensheng Deng
The American Surgeon™.2024; 90(11): 2969. CrossRef - Nutritional Status Indicators Predict Tolerability to Adjuvant Chemotherapy in Patients with Stage II/III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy
Shinya Abe, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Hiroyuki Matsuzaki, Yuzo Nagai, Takahide Shinagawa, Hirofumi Sonoda, Soichiro Ishihara
Digestion.2024; 105(5): 345. CrossRef - Abdominal Aortic Calcification as a Predictor of Incomplete Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Retrospective Cohort Study
Kouki Imaoka, Manabu Shimomura, Hiroshi Okuda, Takuya Yano, Shintaro Akabane, Masahiro Ohira, Yuki Imaoka, Tetsuya Mochizuki, Minoru Hattori, Hideki Ohdan
Cureus.2024;[Epub] CrossRef - Effect of continuous wound infiltration on patients using intravenous patient-controlled analgesia for pain management after reduced-port laparoscopic colorectal surgery
Hyeon Deok Choi, Sung Uk Bae
Annals of Coloproctology.2024; 40(6): 564. CrossRef - Differences in prognosis and underuse of adjuvant chemotherapy between elderly and non‐elderly patients in stage III colorectal cancer
Takuya Shiraishi, Hiroomi Ogawa, Ikuma Shioi, Naoya Ozawa, Katsuya Osone, Takuhisa Okada, Makoto Sohda, Ken Shirabe, Hiroshi Saeki
Annals of Gastroenterological Surgery.2023; 7(1): 91. CrossRef - Clinical outcomes and cost comparison of laparoscopic versus open surgery in elderly colorectal cancer patients over 80 years
Aik Yong Chok, Ivan En-Howe Tan, Yun Zhao, Madeline Yen Min Chee, Hui Lionel Raphael Chen, Kwok Ann Ang, Marianne Kit Har Au, Emile John Kwong Wei Tan
International Journal of Colorectal Disease.2023;[Epub] CrossRef - Association between social background and implementation of postoperative adjuvant chemotherapy for older patients undergoing curative resection of colorectal cancers, sub-analysis of the HiSCO-04 study
Tomoaki Bekki, Manabu Shimomura, Yasufumi Saito, Masahiro Nakahara, Tomohiro Adachi, Satoshi Ikeda, Yosuke Shimizu, Masatoshi Kochi, Yasuyo Ishizaki, Masanori Yoshimitsu, Yuji Takakura, Wataru Shimizu, Daisuke Sumitani, Shinya Kodama, Masahiko Fujimori, M
International Journal of Colorectal Disease.2023;[Epub] CrossRef - Operative and Survival Outcomes of Robotic-Assisted Surgery for Colorectal Cancer in Elderly and Very Elderly Patients: A Study in a Tertiary Hospital in South Korea
Hugo Cuellar-Gomez, Siti Mayuha Rusli, María Esther Ocharan-Hernández, Tae-Hoon Lee, Guglielmo Niccolò Piozzi, Seon-Hahn Kim, Cruz Vargas-De-León, Yazhou He
Journal of Oncology.2022; 2022: 1. CrossRef - Multidisciplinary treatment strategy for early colon cancer
Gyung Mo Son, Su Bum Park, Tae Un Kim, Byung-Soo Park, In Young Lee, Joo-Young Na, Dong Hoon Shin, Sang Bo Oh, Sung Hwan Cho, Hyun Sung Kim, Hyung Wook Kim
Journal of the Korean Medical Association.2022; 65(9): 558. CrossRef - Multidisciplinary Treatment Strategy for Early Colon Cancer: A Review-An English Version
Gyung Mo Son, Su Bum Park, Tae Un Kim, Byung-Soo Park, In Young Lee, Joo-Young Na, Dong Hoon Shin, Sang Bo Oh, Sung Hwan Cho, Hyun Sung Kim, Hyung Wook Kim
Journal of the Anus, Rectum and Colon.2022; 6(4): 203. CrossRef - Adjuvant Chemotherapy in Elderly Colorectal Cancer Patients
Bengt Glimelius, Erik Osterman
Cancers.2020; 12(8): 2289. CrossRef
- Outcome of robotic colon surgery in older patients with colon cancer
- Indication for and Effect of Adjuvant Chemotherapy for Stage IIa (T3N0M0) Colon Cancer
- Chul-Hyo Jeon, Min Ki Kim, In Kyu Lee
- Ann Coloproctol. 2019;35(5):254-261. Published online October 31, 2019
- DOI: https://doi.org/10.3393/ac.2018.12.04
- 9,916 View
- 95 Download
- 2 Web of Science
- 2 Citations
-
Abstract
PDF
- Purpose
The efficacy of adjuvant chemotherapy (AC) in stage IIa colon cancer is controversial. This study aimed to investigate the factors influencing survival in patients with stage IIa colon cancer, the role of AC, and the indications for AC utilization by surgical oncologists.
Methods
Between January 2004 and December 2010, 736 patients with stage IIa colon cancer underwent curative resection in 1 of 6 participating hospitals. Factors related to survival were identified and analyzed according to whether AC was administered or not. After high- and low-risk groups were identified, their respective results were analyzed.
Results
The 5-year overall survival (OS) of stage IIa colon cancer was 90.3%. With the exception of poorly differentiated histology, indications for AC did not include typical high-risk factors. The indications for AC were significantly younger patients, higher body mass index (BMI), lower American Society of Anesthesiologists (ASA) physical status classification, and higher histologic grade. BMI, preoperative carcinoembryonic antigen, and harvested lymph node (LN) count were significant factors for disease-free survival, while BMI and ASA physical status classification were significant factors for OS in the chemotherapy group. In the high-risk group, AC was associated with increased OS in univariate analysis. BMI and harvested LN count were statistically significant in multivariate analysis.
Conclusion
Surgical oncologists consider the patient’s condition and postoperative course rather than high-risk factors to determine use of AC. Regardless of AC use, both the extent of surgery and the patient’s subsequent status affected the survival rate in the high-risk group. None of the factors identified influenced survival rate in the low-risk group. -
Citations
Citations to this article as recorded by- Use of ascitic CEA levels as a predictive value for distant metastasis in high-risk stage II and III colorectal cancer
Abdullah Al-Sawat, Jung Hoon Bea, Seung-Rim Han, Hyo Jin Lee, Mi Ran Yoon, Yoon Suk Lee, Do Sang Lee, Chul Seung Lee, In Kyu Lee
International Journal of Colorectal Disease.2022; 37(2): 365. CrossRef - Prognostic Factor and Survival Benefit of Adjuvant Chemotherapy in Stage IIA Colon Cancer
Mok-Won Lee, Jin-Su Kim, Ji-Yeon Kim, Kyung-ha Lee
Annals of Coloproctology.2021; 37(1): 35. CrossRef
- Use of ascitic CEA levels as a predictive value for distant metastasis in high-risk stage II and III colorectal cancer
- Efficacy and Feasibility of Adding Induction Chemotherapy to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Phase II Clinical Trial
- Hamid Nasrolahi, Sepideh Mirzaei, Mohammad Mohammadianpanah, Ali Mohammad Bananzadeh, Maral Mokhtari, Mohammad Reza Sasani, Ahmad Mosalaei, Shapour Omidvari, Mansour Ansari, Niloofar Ahmadloo, Seyed Hasan Hamedi, Nezhat Khanjani
- Ann Coloproctol. 2019;35(5):242-248. Published online October 31, 2019
- DOI: https://doi.org/10.3393/ac.2018.09.06
- 6,342 View
- 92 Download
- 5 Web of Science
- 5 Citations
-
Abstract
PDF
- Purpose
Currently, neoadjuvant chemoradiation (CRT) followed by total mesorectal resection is considered the standard of care for treating locally advanced rectal cancer. This study aimed to investigate the efficacy and feasibility of adding induction chemotherapy to neoadjuvant CRT in locally advanced rectal cancer.
Methods
This phase-II clinical trial included 54 patients with newly diagnosed, locally advanced (clinical T3–4 and/or N1–2, M0) rectal cancer. All patients were treated with 3 cycles of preoperative chemotherapy using the XELOX (capecitabine + oxaliplatin) regimen before and after a concurrent standard long course of CRT (45–50.4 Gy) followed by standard radical surgery. Pathologic complete response (PCR) rate and toxicity were the primary and secondary endpoints, respectively.
Results
The study participants included 37 males and 17 females, with a median age of 59 years (range, 20–80 years). Twenty-nine patients (54%) had clinical stage-II disease, and 25 patients (46%) had clinical stage-III disease. Larger tumor size (P = 0.006) and distal rectal location (P = 0.009) showed lower PCR compared to smaller tumor size and upper rectal location. Pathologic examinations showed significant tumor regression (6.1 ± 2.7 cm vs. 1.9 ± 1.8 cm, P < 0.001) with 10 PCRs (18.5%) compared to before the intervention. The surgical margin was free of cancer in 52 patients (96.3%). Treatment-related toxicities were easily tolerated, and all patients completed their planned treatment without interruption. Grade III and IV toxicities were infrequent.
Conclusion
The addition of induction chemotherapy to neoadjuvant CRT is an effective and well-tolerated treatment approach in patients with rectal cancer. -
Citations
Citations to this article as recorded by- Nanomedicine integrating the lipidic derivative of 5-fluorouracil, miriplatin and PD-L1 siRNA for enhancing tumor therapy
An Lu, Yuhao Guo, Yi Yan, Lin Zhai, Xiangyu Wang, Weiran Cao, Zijie Li, Zhixia Zhao, Yujie Shi, Yuanjun Zhu, Xiaoyan Liu, Huining He, Zhiyu Wang, Jian-Cheng Wang
Chinese Chemical Letters.2024; 35(6): 108928. CrossRef - Watch and wait strategies for rectal cancer: A systematic review
In Ja Park
Precision and Future Medicine.2022; 6(2): 91. CrossRef - Intensified Total Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer: A Phase II Trial
F. De Felice, G. D'Ambrosio, F. Iafrate, A. Gelibter, F.M. Magliocca, D. Musio, S. Caponetto, G. Casella, I. Clementi, A. Picchetto, G. Sirgiovani, M. Parisi, C. Orciuoli, G. Torrese, G. De Toma, V. Tombolini, E. Cortesi
Clinical Oncology.2021; 33(12): 788. CrossRef - Efficacy and safety of sequential neoadjuvant chemotherapy and short-course radiation therapy followed by delayed surgery in locally advanced rectal cancer: a single-arm phase II clinical trial with subgroup analysis between the older and young patients
Alimohammad Bananzadeh, Ali Akbar Hafezi, NamPhong Nguyen, Shapour Omidvari, Ahmad Mosalaei, Niloofar Ahmadloo, Mansour Ansari, Mohammad Mohammadianpanah
Radiation Oncology Journal.2021; 39(4): 270. CrossRef - Induction Chemotherapy in Patients With Anal Canal Cancer: A Pilot Study
Francesca De Felice, Daniela Musio, Vincenzo Tombolini
Clinical Colorectal Cancer.2020; 19(3): e137. CrossRef
- Nanomedicine integrating the lipidic derivative of 5-fluorouracil, miriplatin and PD-L1 siRNA for enhancing tumor therapy
- Clinical Outcomes of Ileostomy Closure According to Timing During Adjuvant Chemotherapy After Rectal Cancer Surgery
- Yoo Jin Choi, Jung-Myun Kwak, Neul Ha, Tae Hoon Lee, Se Jin Baek, Jin Kim, Seon Hahn Kim
- Ann Coloproctol. 2019;35(4):187-193. Published online August 31, 2019
- DOI: https://doi.org/10.3393/ac.2018.10.18.1
- 7,628 View
- 187 Download
- 12 Web of Science
- 13 Citations
-
Abstract
PDF
- Purpose
No guidelines exist detailing when to implement a temporary ileostomy closure in the setting of adjuvant chemotherapy following sphincter-saving surgery for rectal cancer. The aim of this study was to evaluate the clinical and oncological outcomes of ileostomy closure during adjuvant chemotherapy in patients with curative resection of rectal cancer.
Methods
This retrospective study investigated 220 patients with rectal cancer undergoing sphincter-saving surgery with protective loop ileostomy from January 2007 to August 2016. Patients were divided into 2 groups: group 1 (n = 161) who underwent stoma closure during adjuvant chemotherapy and group 2 (n = 59) who underwent stoma closure after adjuvant chemotherapy.
Results
No significant differences were observed in operative time, blood loss, postoperative hospital stay, or postoperative complications in ileostomy closure between the 2 groups. No difference in overall survival (P = 0.959) or disease-free survival (P = 0.114) was observed between the 2 groups.
Conclusion
Ileostomy closure during adjuvant chemotherapy was clinically safe, and interruption of chemotherapy due to ileostomy closure did not change oncologic outcomes. -
Citations
Citations to this article as recorded by- Early closure of protective ileostomy—a benefit for the patient?
Zuzana Adamová, Michaela Filová, Veronika Pechalová, Martin Chrostek, Radim Slováček
European Surgery.2025; 57(4): 172. CrossRef - Clinical Outcomes of Ileostomy Closure during versus after Adjuvant Chemotherapy in Patients with Rectal Cancer
Fan He, Fuyu Yang, Chenglin Tang, Defei Chen, Dongqin Zhao, Junjie Xiong, Yu Zou, Guoquan Huang, Kun Qian, Masanao Nakamura
Canadian Journal of Gastroenterology and Hepatology.2024; 2024: 1. CrossRef - Prophylactic effect of retromuscular mesh placement during loop ileostomy closure on incisional hernia incidence—a multicentre randomised patient- and observer-blind trial (P.E.L.I.O.N trial)
Sven Müller, Dirk Weyhe, Florian Herrle, Philipp Horvath, Robert Bachmann, Viktor von Ehrlich-Treuenstätt, Patrick Heger, Nadir Nasir, Christina Klose, Alexander Ritz, Anja Sander, Erich Grohmann, Colette Dörr-Harim, André L. Mihaljevic
Trials.2023;[Epub] CrossRef - Impact of chemotherapy on surgical outcomes in ileostomy reversal: a propensity score matching study from a single centre
H.-H. Cheng, Y.-C. Shao, C.-Y. Lin, T.-W. Chiang, M.-C. Chen, T.-Y. Chiu, Y.-L. Huang, C.-C. Chen, C.-P. Chen, F.-F. Chiang
Techniques in Coloproctology.2023; 27(12): 1227. CrossRef - Comparison of clinical outcomes of stoma reversal during versus after chemotherapy for rectal cancer patients
Kun-Yu Tsai, Jeng-Fu You, Shu-Huan Huang, Tzong-yun Tsai, Pao-Shiu Hsieh, Cheng-Chou Lai, Wen-Sy Tsai, Hsin-Yuan Hung
Langenbeck's Archives of Surgery.2023;[Epub] CrossRef - Early versus late closure of temporary ileostomy after rectal cancer surgery: a meta-analysis
Li Wang, Xinling Chen, Chen Liao, Qian Wu, Hongliang Luo, Fengming Yi, Yiping Wei, Wenxiong Zhang
Surgery Today.2021; 51(4): 463. CrossRef - Low albumin level and longer interval to closure increase the early complications after ileostomy closure
HyungJoo Baik, Ki Beom Bae
Asian Journal of Surgery.2021; 44(1): 352. CrossRef - Does the timing of protective ileostomy closure post-low anterior resection have an impact on the outcome? A retrospective study
Fozan Sauri, Ahmad Sakr, Ho Seung Kim, Mohammed Alessa, Radwan Torky, Eman Zakarneh, Seung Yoon Yang, Nam Kyu Kim
Asian Journal of Surgery.2021; 44(1): 374. CrossRef - Impact of a defunctioning ileostomy and time to stoma closure on bowel function after low anterior resection for rectal cancer: a systematic review and meta-analysis
I. Vogel, N. Reeves, P. J. Tanis, W. A. Bemelman, J. Torkington, R. Hompes, J. A. Cornish
Techniques in Coloproctology.2021; 25(7): 751. CrossRef - Clinical Outcomes of Ileostomy Closure before Adjuvant Chemotherapy after Rectal Cancer Surgery: An Observational Study from a Chinese Center
Zhen Sun, Yufeng Zhao, Lu Liu, Jichao Qin, Zhongguang Luo
Gastroenterology Research and Practice.2021; 2021: 1. CrossRef - Delayed ileostomy closure increases the odds of Clostridium difficile infection
Simon J. G. Richards, Dilshan K. Udayasiri, Ian T. Jones, Ian A. Hastie, Raaj Chandra, Jacob J. McCormick, Timothy J. Chittleborough, David J. Read, Ian P. Hayes
Colorectal Disease.2021; 23(12): 3213. CrossRef - The effect of ileostomy closure timing on low anterior resection syndrome in patient who underwent low anterior resection for rectal cancer
Hemn Hussain Kaka Ali, Qalandar Hussein Abdulkarim, Karzan Seerwan, Barham M. M .Salih, Omar H Ghalib Hawramy, Dara Ahmed Mohammed, Syamand Orhaman Ahmed
Kurdistan Journal of Applied Research.2021; : 126. CrossRef - Assessment of the risk of permanent stoma after low anterior resection in rectal cancer patients
Marcin Zeman, Marek Czarnecki, Andrzej Chmielarz, Adam Idasiak, Maciej Grajek, Agnieszka Czarniecka
World Journal of Surgical Oncology.2020;[Epub] CrossRef
- Early closure of protective ileostomy—a benefit for the patient?
Review
- Organ Preservation Strategies After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
- Ri Na Yoo, Hyung Jin Kim
- Ann Coloproctol. 2019;35(2):53-64. Published online April 30, 2019
- DOI: https://doi.org/10.3393/ac.2019.04.15.1
- 8,076 View
- 196 Download
- 7 Web of Science
- 7 Citations
-
Abstract
PDF
- Standard use of neoadjuvant chemoradiotherapy, total mesorectal excision, and postoperative adjuvant chemotherapy in locally advanced rectal cancer has tremendously improved oncologic outcomes over the past several decades. However, these improvements come with costs of significant morbidity and poor quality of life. Along with developments in imaging techniques, clinical experience and evidence have identified a certain subgroup of patients that have exceptionally good clinical outcomes while preserving quality of life. Driven by patient demand and interest in preserving quality of life, numerous organ preservation treatment strategies for managing rectal cancer are rapidly evolving. Herein, the flow of research in organ preservation strategies and counter arguments are discussed.
-
Citations
Citations to this article as recorded by- Lateral pelvic lymph node dissection based on nodal response to neoadjuvant chemoradiotherapy in mid/low rectal cancer: a retrospective comparative cohort study
Tae-Gyun Lee, Duck-Woo Kim, Hong-min Ahn, Hye-Rim Shin, Mi Jeong Choi, Min Hyeong Jo, Heung-Kwon Oh, Sung-Bum Kang
Annals of Surgical Treatment and Research.2025; 108(6): 333. CrossRef - Efficacy and safety of MR-guided adaptive simultaneous integrated boost radiotherapy to primary lesions and positive lymph nodes in the neoadjuvant treatment of locally advanced rectal cancer: a randomized controlled phase III trial
Haohua Wang, Xiang Zhang, Boyu Leng, Kunli Zhu, Shumei Jiang, Rui Feng, Xue Dou, Fang Shi, Lei Xu, Jinbo Yue
Radiation Oncology.2024;[Epub] CrossRef - Organ preservation for early rectal cancer using preoperative chemoradiotherapy
Gyung Mo Son
Annals of Coloproctology.2023; 39(3): 191. CrossRef - Komplette Response nach neoadjuvanter Therapie beim Rektumkarzinom: Implikationen für die Chirurgie
Carolin Kastner, Bernhard Petritsch, Joachim Reibetanz, Christoph-Thomas Germer, Armin Wiegering
Der Chirurg.2022; 93(2): 144. CrossRef - Evaluating the benefit of adjuvant chemotherapy in patients with ypT0–1 rectal cancer treated with preoperative chemoradiotherapy
Ye Won Jeon, In Ja Park, Jeong Eun Kim, Jin-Hong Park, Seok-Byung Lim, Chan Wook Kim, Yong Sik Yoon, Jong Lyul Lee, Chang Sik Yu, Jin Cheon Kim
World Journal of Gastrointestinal Surgery.2021; 13(9): 1000. CrossRef - Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiotherapy in Patients With Rectal Cancer: A Single-Center Experience and Literature Review
Min Chul Kim, Jae Hwan Oh
Annals of Coloproctology.2021; 37(6): 382. CrossRef - The apparent diffusion coefficient is a useful biomarker in predicting treatment response in patients with locally advanced rectal cancer
Mayra Evelia Jiménez de los Santos, Juan Armando Reyes-Pérez, Rosa Martha Sandoval-Nava, José Luis Villalobos-Juárez, Yolanda Villaseñor-Navarro, Itzel Vela-Sarmiento, Isabel Sollozo-Dupont
Acta Radiologica Open.2020;[Epub] CrossRef
- Lateral pelvic lymph node dissection based on nodal response to neoadjuvant chemoradiotherapy in mid/low rectal cancer: a retrospective comparative cohort study
Original Articles
- Chemotherapeutic Response and Survival for Patients With an Anal Squamous Cell Carcinoma and Low Hemoglobin Levels
- Ali Zain Naqvi, Esther Platt, Maki Jitsumura, Martyn Evans, Mark Coleman, Sebastian Smolarek
- Ann Coloproctol. 2018;34(6):312-316. Published online December 31, 2018
- DOI: https://doi.org/10.3393/ac.2017.10.12
- 4,364 View
- 72 Download
- 1 Web of Science
- 1 Citations
-
Abstract
PDF
- Purpose
Anemia is associated with poor treatment results for a variety of cancers. The effect of low hemoglobin levels on long-term outcomes after the treatment of patients with an anal squamous cell carcinoma (SCC) remains unclear. For that reason, this study aimed to investigate the effect of anemia on treatment outcomes following chemoradiation for an anal SCC.
Methods
This was a retrospective study of all patients who underwent curative treatment for an anal SCC between 2009 and 2015 at 2 trusts in the United Kingdom. Data were collated from prospectively collected cancer databases and were cross-checked with operating-room records and records in the hospitals’ patient management systems.
Results
We identified 103 patients with a median age of 63 years (range, 36–84 years). The median overall survival was 39 months (range, 9–90 months), and the disease-free survival was 36 months (range, 2–90 months). During the follow-up period, 16.5% patients died and 13.6% patients developed recurrence. Twenty-two people were anemic prior to treatment, with a female preponderance (20 of 22). No differences in disease-free survival (P = 0.74) and overall survival (P = 0.12) were noted between patients with anemia and those with normal hemoglobin levels. On regression the analysis, the combination of anemia, the presence of a defunctioning colostomy, lymph-node involvement and higher tumor stage correlated with poor overall survival.
Conclusion
In this study, anemia did not influence disease-free survival or overall survival. We suggest that the interaction between anemia and survival is more complex than previously demonstrated and potentially reliant on other coexisting factors. -
Citations
Citations to this article as recorded by- Prognostic and Predictive Clinical and Biological Factors in HPV Malignancies
Shivani Sud, Ashley A. Weiner, Andrew Z. Wang, Gaorav P. Gupta, Colette J. Shen
Seminars in Radiation Oncology.2021; 31(4): 309. CrossRef
- Prognostic and Predictive Clinical and Biological Factors in HPV Malignancies
- Impact of Adjuvant Therapy Type on Survival in Stage II/III Rectal Cancer Without Preoperative Chemoradiation: A Korean Multicenter Retrospective Study
- Byung Mo Kang, Jeong-Heum Baek, Sun Jin Park, Seong Kyu Baek, Ki-Jae Park, Hong-Jo Choi, Byung-Noe Bae, Sun Keun Choi, Kap Tae Kim, Jin-Su Kim, Suk-Hwan Lee
- Ann Coloproctol. 2018;34(3):144-151. Published online June 30, 2018
- DOI: https://doi.org/10.3393/ac.2017.09.26.1
- 6,628 View
- 107 Download
- 4 Web of Science
- 4 Citations
-
Abstract
PDF
- Purpose
This study compared the oncologic impact of postoperative chemotherapy and chemoradiotherapy on patients with rectal cancer without preoperative chemoradiation.
Methods
This retrospective study analyzed 713 patients with a mean follow-up of 58 months who had undergone radical resection for stage II/III rectal cancer without preoperative treatment in nine hospitals from January 2004 to December 2009. The study population was categorized a chemotherapy group (CG, n = 460) and a chemoradiotherapy group (CRG, n = 253). Five-year overall survival (OS) and disease-free survival (DFS) were analyzed, and independent factors predicting survival were identified.
Results
The patients in the CRG were significantly younger (P < 0.001) and had greater incidences of low rectal cancer (P < 0.001) and stage III disease (P < 0.001). Five-year OS (P = 0.024) and DFS (P = 0.012) were significantly higher in the CG for stage II disease; however, they were not significantly different for stage III disease. In the multivariate analysis, independent predictive factors were male sex, low rectal cancer and stage III disease for OS and male sex, abdominoperineal resection, stage III disease and tumor-positive circumferential margin for DFS. However, adjuvant therapy type did not independently affect OS (hazard ratio [HR], 1.243; 95% confidence interval [CI], 0.794–1.945; P = 0.341) and DFS (HR, 1.091; 95% CI, 0.810–1.470; P = 0.566).
Conclusion
Adjuvant therapy type did not affect survival of stage II/III rectal cancer patients without neoadjuvant chemoradiotherapy. These results suggest that adjuvant therapy can be chosen based on the patient’s condition and the policies of the surgeons and hospital facilities. -
Citations
Citations to this article as recorded by- Efficacies of radiotherapy in rectal cancer patients treated with total mesorectal excision or other types of surgery: an updated meta-analysis
Wenshu Wang, Runyuan Zhao, Xi Liang, Manjun Liu, Haiyan Bai, Jianli Ge, Binxi Yao, Zheng Zhi, Jianming He
Oncology Reviews.2025;[Epub] CrossRef - Management and Outcomes of Pathologic Upstaging of Clinical Stage I Rectal Cancers: An Exploratory Analysis
Alisha Lussiez, Samantha J. Rivard, Kamren Hollingsworth, Sherif R.Z. Abdel-Misih, Philip S. Bauer, Katherine A. Hrebinko, Glen C. Balch, Lillias H. Maguire
Diseases of the Colon & Rectum.2023; 66(4): 543. CrossRef - The oncological outcomes of postoperative radiotherapy in patients with stage II and III upper rectal cancer
Ilknur ALSAN CETIN, Sıtkı Utku AKAY
Marmara Medical Journal.2022;[Epub] CrossRef - Selection of Adjuvant Treatment Without Neoadjuvant Chemoradiotherapy for Patients With Rectal Cancer: Room for Further Investigation
In Ja Park
Annals of Coloproctology.2018; 34(3): 109. CrossRef
- Efficacies of radiotherapy in rectal cancer patients treated with total mesorectal excision or other types of surgery: an updated meta-analysis
- Perioperative Serum Carcinoembryonic Antigen Ratio Is a Prognostic Indicator in Patients With Stage II Colorectal Cancer
- Jinsun Woo, Jungbin Kim, Inseok Park, Hyunjin Cho, Geumhee Gwak, Keun Ho Yang, Byung-Noe Bae, Ki Hwan Kim
- Ann Coloproctol. 2018;34(1):4-10. Published online February 28, 2018
- DOI: https://doi.org/10.3393/ac.2018.34.1.4
- 8,083 View
- 83 Download
- 6 Web of Science
- 3 Citations
-
Abstract
PDF
Purpose The aim of this study was to evaluate whether the perioperative carcinoembryonic antigen (CEA) ratio could be used as a determinant for adjuvant therapy after curative surgery in stage II colorectal cancer.
Methods Data for 119 patients with stage II colorectal cancer who underwent radical surgery between 2010 and 2013 were collected. The perioperative CEA ratio was defined as the postoperative/preoperative serum CEA level, and the patients were grouped according to their perioperative CEA ratios: high ratio (≥0.5) and low ratio (<0.5). Overall survival rates were calculated, and their prognostic significances were analyzed.
Results The overall survival rates of the high and the low perioperative CEA groups were 68.2% and 86.8%, respectively (P = 0.033). In patients with normal preoperative CEA levels (<5 ng/mL), the high perioperative CEA ratio group showed a worse survival rate than the low perioperative CEA ratio group (71.7% vs. 100.0%, P = 0.007). In patients with high preoperative CEA levels (≥5 ng/mL), the high perioperative CEA ratio group showed a worse survival rate than the low perioperative CEA ratio group (33.3% vs. 75.0%, P = 0.036). In the multivariate analysis, perioperative CEA ratio (P = 0.046), age (P = 0.034), and venous invasion (P = 0.015) were independent prognostic factors for survival.
Conclusion The perioperative CEA ratio is a prognostic indicator for stage II colorectal cancer. Patients with normal preoperative serum CEA levels might also be considered for adjuvant therapy if their perioperative CEA ratios are higher than 0.5.
-
Citations
Citations to this article as recorded by- Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine
Seung E. Cha, Maciej Kujawski, Paul J. Yazaki, Christine Brown, John E. Shively
OncoImmunology.2021;[Epub] CrossRef - Prognostic Impact of Pretreatment Elevated and Normalized Carcinoembryonic Antigen Levels After Neoadjuvant Chemoradiotherapy in Resected Locally Advanced Rectal Cancer Patients
Jianyuan Song, Zhuhong Chen, Daxin Huang, Benhua Xu
Cancer Management and Research.2021; Volume 13: 3713. CrossRef - Association between Primary Perioperative CEA Ratio, Tumor Site, and Overall Survival in Patients with Colorectal Cancer
Thomas A. Odeny, Nicole Farha, Hannah Hildebrandand, Jessica Allen, Wilfred Vazquez, Maximillian Martinez, Ravi Kumar Paluri, Anup Kasi
Journal of Clinical Medicine.2020; 9(12): 3848. CrossRef
- Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine
Case Report
- Xanthogranulomatous Appendicitis Mimicking Residual Burkitt's Lymphoma After Chemotherapy
- Soomin Nam, Jeonghyun Kang, Sung-Eun Choi, Yu Ri Kim, Seung Hyuk Baik, Seung-Kook Sohn
- Ann Coloproctol. 2016;32(2):83-86. Published online April 30, 2016
- DOI: https://doi.org/10.3393/ac.2016.32.2.83
- 5,032 View
- 43 Download
- 5 Web of Science
- 9 Citations
-
Abstract
PDF
The case of a 23-year-old female treated with aggressive high-dose therapy for Burkitt's lymphoma is reported. A positron emission tomography and computed tomography scan after completion of chemotherapy revealed a residual hypermetabolic lesion in the right pelvic cavity. A pelvic magnetic resonance imaging scan showed circumferential wall thickening at the tip of the appendix. A laparoscopic exploration and appendectomy were performed, and a pathologic examination of the resected appendix revealed xanthogranulomatous appendicitis. This is a rare case of a xanthogranulomatous appendicitis mimicking remnant Burkitt's lymphoma after completion of chemotherapy.
-
Citations
Citations to this article as recorded by- Xanthogranulomatous appendicitis presenting asymptomatically 3 years after surgery for hilar cholangiocarcinoma: A case report
Nobuhisa Tanioka, Michio Kuwahara, Takashi Sakai, Yuzuko Nokubo, Makoto Hiroi, Toyokazu Akimori
International Journal of Surgery Case Reports.2024; 120: 109800. CrossRef - Xanthogranulomatous appendicitis
Elina Sor, Igor Mishin
Bulletin of the Academy of Sciences of Moldova. Medical Sciences.2024; 77(3): 265. CrossRef - A case of xanthogranulomatous appendicitis that was difficult to diagnose
Yusaku WATANABE, Shingo SHIOYA, Tetsuhito ARIKIZONO, Syuzou TASHIMA, Toshiyuki CHOSA, Hiroshi SUGITA, Kyouko MIZUKAMI, Kentaro TOKUDOME, Kaoru HIJIKURO, Kouichirou SHIGETA
Choonpa Igaku.2023; 50(2): 121. CrossRef - Focal Xanthogranulomatous Pyelonephritis on FDG PET/CT
Yong Liu, Guansheng Tong, Zhe Wen
Clinical Nuclear Medicine.2022; 47(9): e611. CrossRef - Xanthogranulomatous appendicitis misdiagnosed as a malignant tumor: A case report
Subo Wang, Tingchong Jiang, Xiaoxuan Zhou, Xiaoming Mao
Asian Journal of Surgery.2022; 45(8): 1650. CrossRef - A Case of Laparoscopic Cecectomy for Xanthogranulomatous Appendicitis
Marina ISOKAWA, Aya SATO, Ken IMAIZUMI, Kentaro SATO, Hiroyuki KASAJIMA, Hanae KUSHIBIKI, Norihiko SHIMOYAMA, Kazuaki NAKANISHI
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2022; 83(11): 1948. CrossRef - Xanthogranulomatous appendicitis: A comprehensive literature review
Sami Akbulut, Khaled Demyati, Cemalettin Koc, Adem Tuncer, Emrah Sahin, Mehmet Ozcan, Emine Samdanci
World Journal of Gastrointestinal Surgery.2021; 13(1): 76. CrossRef - A Case of Xanthogranulomatous Appendicitis That Was Difficult to Differentiate from Appendiceal Mucocele
Hirofumi Doi, Kazuhiro Toyota, Satoshi Hirahara, Yuta Kuhara, Kenji Shirakawa, Tetsuhiro Hara, Hironori Kobayashi, Yoshihiro Sakashita, Motoki Ninomiya, Fumio Shimamoto, Katsunari Miyamoto
The Japanese Journal of Gastroenterological Surgery.2021; 54(3): 208. CrossRef - A Case of Xanthogranulomatous Appendicitis
Shoichiro NAKAJO, HoMin KIM, Ryoji NONAKA, Jun KAJIHARA, Masami IMAKITA, Toshikazu ITO, Masahiro TANEMURA
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2019; 80(12): 2233. CrossRef
- Xanthogranulomatous appendicitis presenting asymptomatically 3 years after surgery for hilar cholangiocarcinoma: A case report
Original Articles
- Insertion of Totally Implantable Central Venous Access Devices by Surgeons
- Hyeonjun An, Chun-Geun Ryu, Eun-Joo Jung, Hyun Jong Kang, Jin Hee Paik, Jung-Hyun Yang, Dae-Yong Hwang
- Ann Coloproctol. 2015;31(2):63-67. Published online April 30, 2015
- DOI: https://doi.org/10.3393/ac.2015.31.2.63
- 6,892 View
- 49 Download
- 16 Web of Science
- 18 Citations
-
Abstract
PDF
Purpose The aim of this study is to evaluate the results for the insertion of totally implantable central venous access devices (TICVADs) by surgeons.
Methods Total 397 patients, in whom TICVADs had been inserted for intravenous chemotherapy between September 2008 and June 2014, were pooled. This procedure was performed under local anesthesia in an operation room. The insertion site for the TICVAD was mainly in the right-side subclavian vein. In the case of breast cancer patients, the subclavian vein opposite the surgical site was used for insertion.
Results The 397 patients included 73 males and 324 females. Primary malignant tumors were mainly colorectal and breast cancer. The mean operation time was 54 minutes (18-276 minutes). Operation-related complications occurred in 33 cases (8.3%). Early complications developed in 15 cases with catheter malposition and puncture failure. Late complications, which developed after 24 hours, included inflammation in 6 cases, skin necrosis in 6 cases, hematoma in 3 cases, port malfunction in 1 case, port migration in 1 case, and intractable pain at the port site in 1 case.
Conclusion Insertion of a TICVAD under local anesthesia by a surgeon is a relatively safe procedure. Meticulous undermining of the skin and carefully managing the TICVAD could minimize complications.
-
Citations
Citations to this article as recorded by- Implantable catheter chambers: a 14-year descriptive study
Anas Erragh, Salma Bellaftouh, Safia Chaabi, Yassine Hafiani, Afak Nsiri, Rachid Alharrar
memo - Magazine of European Medical Oncology.2025; 18(1): 56. CrossRef - Vascular access device type for systemic anti-cancer therapies in cancer patients: A scoping review
C. Duggan, O. Hernon, R. Dunne, V. McInerney, S.R. Walsh, A. Lowery, M. McCarthy, P.J. Carr
Critical Reviews in Oncology/Hematology.2024; 196: 104277. CrossRef - Machine learning risk prediction model for bloodstream infections related to totally implantable venous access ports in patients with cancer
Fan Wang, Yanyi Zhu, Lijuan Wang, Caiying Huang, Ranran Mei, Li-e Deng, Xiulan Yang, Yan Xu, Lingling Zhang, Min Xu
Asia-Pacific Journal of Oncology Nursing.2024; 11(8): 100546. CrossRef - Catheter malposition analysis of totally implantable venous access port in breast cancer patients
Wenbo Liu, Qingzheng Han, Lin Li, Jiangrui Chi, Xinwei Liu, Yuanting Gu
Frontiers in Surgery.2023;[Epub] CrossRef - Portocath insertion technique: retrospective study & step-by-step surgical description without tunneling in a high-complexity service
ANNA MARIA GARCIA CARDOSO, FERNANDA SANTOS WENGROVER, ALINE WÜRZIUS, MARINA PUERARI PIETA, RAFFAELA NASCIMENTO DE CARLI, CARLOS EDUARDO BASTIAN DA-CUNHA, RICARDO BREIGEIRON
Revista do Colégio Brasileiro de Cirurgiões.2022;[Epub] CrossRef - Sağ Atriumdan Sağ Juguler Vene Yolculuk: Nadir Bir Port Kateter Komplikasyonu
Orhan ÜREYEN, Hüseyin FENERCİOĞLU, Demet ALAY, İlhan DURSUN, Enver İLHAN
Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi.2021; 54(1): 148. CrossRef - Forty years after the first totally implantable venous access device (TIVAD) implant: the pure surgical cut-down technique only avoids immediate complications that can be fatal
Adriana Toro, Elena Schembari, Emanuele Gaspare Fontana, Salomone Di Saverio, Isidoro Di Carlo
Langenbeck's Archives of Surgery.2021; 406(6): 1739. CrossRef - An analysis of the outcomes of totally implantable access port implantation performed by surgical residents
Se-Beom Jeon, Youngbae Jeon, Kyoung-Won Han, Yong-Soon Chun, Jeong-Heum Baek
Korean Journal of Clinical Oncology.2021; 17(1): 15. CrossRef - Totally implantable venous access devices
Swapnil Patel, Preeti Vijayakumaran
Cancer Research, Statistics, and Treatment.2021; 4(3): 536. CrossRef - Long-Term Management of Vascular Access Ports in Nonhuman Primates Used in Preclinical Efficacy and Tolerability Studies
Lucas A. Mutch, Samuel T. Klinker, Jody J. Janecek, Melanie N. Niewinski, Rachael M. Z. Lee, Melanie L. Graham
Journal of Investigative Surgery.2020; 33(6): 493. CrossRef - Validation of a questionnaire of knowledge and attitudes about the subcutaneous venous reservoir in nursing
Roberto Raña-Rocha, Ignacio López-de-Ullibarri, María-Jesús Movilla-Fernández, Carmen Coronado Carvajal
Revista Latino-Americana de Enfermagem.2020;[Epub] CrossRef - Comparison of Care Outcomes Between Two Methods of Drug Injection Through Ports and Peripheral Veins in Patients Undergoing Chemotherapy
Seied Hashem Mosavi, Nasrin Elahi, Marziyeh Asadizaker, Ahmad Ahmadzadeh Deilami
Jundishapur Journal of Chronic Disease Care.2020;[Epub] CrossRef - Supraclavicular versus infraclavicular approach in inserting totally implantable central venous access for cancer therapy: A comparative retrospective study
Amine Souadka, Hajar Essangri, Imad Boualaoui, Abdelilah Ghannam, Amine Benkabbou, Laila Amrani, Raouf Mohsine, Mohammed Anass Majbar, Robert Jeenchen Chen
PLOS ONE.2020; 15(11): e0242727. CrossRef - Ultrasound‐guided totally implantable venous access device through the right innominate vein in older patients is safe and reliable
Xingwei Sun, Yu Zhang, Chuanlai Yang, Yubin Zhou, Xuming Bai, Weiwei Zheng, Yong Jin
Geriatrics & Gerontology International.2019; 19(3): 218. CrossRef - An unusual catheter malposition following totally implantable venous access port insertion: The catheter tip located into the right axillary vein
Ahmet Yüksel, Yusuf Velioğlu, Mustafa Enes Demirel, Erhan Renan Uçaroğlu
Journal of Surgery and Medicine.2019;[Epub] CrossRef - Usefulness of Percutaneous Puncture in Insertion of Totally Implantable Venous Access Devices in Pediatric Patients
Jung Sik Choi, Keun-Myoung Park, Sungteak Jung, Kee Chun Hong, Yong Sun Jeon, Soon Gu Cho, Yun-Mee Choe
Vascular Specialist International.2017; 33(3): 108. CrossRef - Reply on "What Is the Role of Surgeons When Implanting a Totally Implantable Venous Access Device to Prevent Immediate Complications?"
Eun-Joo Jung, Dae-Yong Hwang
Annals of Coloproctology.2015; 31(4): 165. CrossRef - Commentary on "Insertion of Totally Implantable Central Venous Access Devices by Surgeons" - What Is the Role of Surgeons When Implanting a Totally Implantable Venous Access Device to Prevent Immediate Complications?
Adriana Toro, Gaetano Bertino, Annalisa Ardiri, Isidoro Di Carlo
Annals of Coloproctology.2015; 31(4): 163. CrossRef
- Implantable catheter chambers: a 14-year descriptive study
- Comparison of Compliance of Adjuvant Chemotherapy Between Laparoscopic and Open Surgery in Patients With Colon Cancer
- Kan Ho Chun, Byung Noe Bae, Hoon An, Hyeonseok Jeong, Hyunjin Cho, Geumhee Gwak, Keun Ho Yang, Ki Hwan Kim, Hong Ju Kim, Young Duk Kim
- Ann Coloproctol. 2014;30(6):274-279. Published online December 31, 2014
- DOI: https://doi.org/10.3393/ac.2014.30.6.274
- 4,494 View
- 49 Download
- 6 Web of Science
- 7 Citations
-
Abstract
PDF
Purpose Many studies have shown that the completion of adjuvant chemotherapy improves the survival rate. Recently, laparoscopic surgery has been used to treat patients with colon cancer. We analyzed the relationship between the completion of adjuvant chemotherapy and the operation method.
Methods We retrospectively analyzed the medical records of 147 patients diagnosed with colon cancer from January 1, 2009, to May 31, 2012. The numbers of patients who underwent laparoscopic and open surgery were 91 and 56, respectively. We analyzed the relationship between the operation method and various factors such as the completion rate of chemotherapy, the patient's age, gender, and physical activity, the postoperative hospital stay, the start time of chemotherapy, and the patient's body mass index (BMI), TNM stage, and type of health insurance.
Results In the laparoscopic surgery group, the postoperative hospital stay (13.5 ± 14.82 days vs. 19.6 ± 11.38 days, P = 0.001) and start time of chemotherapy (17.7 ± 17.48 days vs. 23.0 ± 15.00 days, P = 0.044) were shorter, but the percent complete of chemotherapy (71/91 [78.0%] vs. 38/56 [67.8%], P = 0.121), and survival rate (88/91 [96.7%], 47/56 [83.9%], P = 0.007) were higher than they were in the open surgery group. Patients who were elderly, had a low BMI, and a high American Society of Anesthesiologists score were less likely to complete adjuvant chemotherapy than other patients were.
Conclusion Laparoscopic surgery shows a shorter postoperative hospital stay, a shorter start time of chemotherapy, and a higher survival rate. Laparoscopic surgery may be expected to increase compliance of chemotherapy and to improve survival rate.
-
Citations
Citations to this article as recorded by- Return to intended oncologic therapy after colectomy for stage III colon adenocarcinoma: Does surgical approach matter?
David T. Pointer, Seth I. Felder, Benjamin D. Powers, Sophie Dessureault, Julian A. Sanchez, Iman Imanirad, Ibrahim Sahin, Hao Xie, Samer A. Naffouje
Colorectal Disease.2023; 25(9): 1760. CrossRef - A comparison of minimally invasive vs open distal pancreatectomy for resectable pancreatic ductal adenocarcinoma: Propensity score matching analysis
Jaewoo Kwon, Seo Young Park, Yejong Park, Eunsung Jun, Woohyung Lee, Ki Byung Song, Jae Hoon Lee, Dae Wook Hwang, Song Cheol Kim
Journal of Hepato-Biliary-Pancreatic Sciences.2021; 28(11): 967. CrossRef - N1c colon cancer and the use of adjuvant chemotherapy: a current audit of the National Cancer Database
Hillary L. Simon, Thais Reif de Paula, Zachary A. Spigel, Deborah S. Keller
Colorectal Disease.2021; 23(3): 653. CrossRef - Comparison of Minimally Invasive versus Open Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Propensity Score Matching Analysis
Jaewoo Kwon, Ki Byung Song, Seo Young Park, Dakyum Shin, Sarang Hong, Yejong Park, Woohyung Lee, Jae Hoon Lee, Dae Wook Hwang, Song Cheol Kim
Cancers.2020; 12(4): 982. CrossRef - Short-term results of laparoscopic and open complete mesocolic excision with D3 lymph node dissection for left-sided colon cancer
P. V. Tsarkov, I. A. Tulina, A. Yu. Kravchenko, A. V. Leont’Yev
Russian Journal of Gastroenterology, Hepatology, Coloproctology.2016; 26(1): 99. CrossRef - Impact of type of surgery (laparoscopic versus open) on the time to initiation of adjuvant chemotherapy in operable rectal cancers
Snita Sinukumar, Shaesta Mehta, Vikas Ostwal, Sudhir Jatal, Avanish Saklani
Indian Journal of Gastroenterology.2015; 34(4): 310. CrossRef - Effect of Laparoscopic Surgery on the Initiation and Completion of Chemotherapy in Patients With Colon Cancer
Min-Ki Kim, Won-Kyung Kang
Annals of Coloproctology.2014; 30(6): 250. CrossRef
- Return to intended oncologic therapy after colectomy for stage III colon adenocarcinoma: Does surgical approach matter?
- Is Microsatellite Instability Really a Good Prognostic Factor of Colorectal Cancer?
- Ui Sup Shin, Sang Sik Cho, Sun Mi Moon, Sun Hoo Park, Sun Hee Jee, Eun-Joo Jung, Dae-Yong Hwang
- Ann Coloproctol. 2014;30(1):28-34. Published online February 28, 2014
- DOI: https://doi.org/10.3393/ac.2014.30.1.28
- 7,176 View
- 43 Download
- 34 Web of Science
- 27 Citations
-
Abstract
PDF
Purpose The aim of this study was to investigate the clinicopathologic features of and the prognosis for colorectal cancers (CRCs) with microsatellite instabilities (MSIs).
Methods Between 2006 and 2009, genotyping was performed on 245 patients with stage II/III CRCs to establish the MSI status. The clinicopathologic differences and the prognostic value of MSI were analyzed. The median follow-up period was 38 months (range, 7-68 months).
Results Of the total 245 patients, 20 (8.2%) had MSI-high (H) and 225 (91.8%) had MSI-low (L) or stable (S) CRCs. Adjuvant chemotherapies were performed on 101 stage II (87.8%) and 107 stage III patients (82.3%). Patients with MSI-H CRCs more frequently had a family history of colon cancer (10% vs. 2.7%, P = 0.003), more frequently had a cancer located at the proximal colon (90.0% vs. 19.1%, P < 0.0001), and more often showed a mucinous phenotype or poor differentiation (35.0% vs. 7.1%, P = 0.001). Despite less frequent lymph node metastasis (25% vs. 55.6%, P = 0.01), the number of retrieved lymph nodes was higher (26.3 ± 13.1 vs. 20.7 ± 1.2, P = 0.04) in the MSI-H group. The overall survival and the disease-free survival (DFS) did not differ with respect to MSI status. However, in the stage II subgroup, the DFS for patients with MSI-H CRCs was significantly worse (72.2% vs. 90.7%, P = 0.03). The multivariate analysis performed on this subgroup revealed that MSI-H was an independent poor prognostic factor (adjusted hazard ratio, 4.0; 95% confidence interval, 1.0-15.6, P = 0.046).
Conclusion MSI-H CRCs had distinct clinicopathologic features, and MSI-H was an independent poor prognostic factor in stage II CRCs. Considering the majority of stage II patients were administrated adjuvant chemotherapy, the efficacy of adjuvant chemotherapy for treating MSI CRCs might be different from that for treating MSI-L/S tumors.
-
Citations
Citations to this article as recorded by- Microsatellite instability–high status enhances lymph node yield and reduces optimal dissection thresholds in colorectal cancer: A retrospective cohort analysis with β-binomial modeling
Xu Sun, Rui Li, Sizhe Wang, Wen Zhao, Hao Liu, Wenxing Gao, Peng Chen, Dingchang Li, Guanglong Dong
Surgery.2026; 190: 109890. CrossRef - Reassessing the Prognostic Value of Lymph Node Metastasis in Deficient Mismatch Repair Colorectal Cancer
Zilan Ye, Dakui Luo, Fan Chen, Jiayu Chen, Zezhi Shan, Junyong Weng, Yu Zhang, Qingguo Li, Xinxiang Li
Current Oncology.2025; 32(5): 254. CrossRef - Prognostic significance of negative lymph node count in microsatellite instability-high colorectal cancer
Xuan Dai, Zhujiang Dai, Jihong Fu, Zhonglin Liang, Peng Du, Tingyu Wu
World Journal of Surgical Oncology.2024;[Epub] CrossRef - Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer
Wen-Xuan Fan, Fei Su, Yan Zhang, Xiao-Ling Zhang, Yun-Yi Du, Yang-Jun Gao, Wei-Ling Li, Wen-Qing Hu, Jun Zhao
Biomarker Research.2024;[Epub] CrossRef - Exploring the value of multiple preprocessors and classifiers in constructing models for predicting microsatellite instability status in colorectal cancer
Yi Ma, Zhihao Shi, Ying Wei, Feng Shi, Guochu Qin, Zhengyang Zhou
Scientific Reports.2024;[Epub] CrossRef - The prognostic significance of microsatellite instability in colorectal cancer: a Swedish multi-center study
Petri Rantanen, Anne Keränen, Shabane Barot, Sam Ghazi, Annelie Liljegren, Caroline Nordenvall, Annika Lindblom, Ulrik Lindforss
International Journal of Colorectal Disease.2023;[Epub] CrossRef - Preoperative albumin–bilirubin score as a prognostic indicator in patients with stage III colon cancer
Hyun Gu Lee, Seok-Byung Lim, Jong Lyul Lee, Chan Wook Kim, Yong Sik Yoon, In Ja Park, Jin Cheon Kim
Scientific Reports.2022;[Epub] CrossRef - Radiomics features based on internal and marginal areas of the tumor for the preoperative prediction of microsatellite instability status in colorectal cancer
Yi Ma, Changsong Lin, Song Liu, Ying Wei, Changfeng Ji, Feng Shi, Fan Lin, Zhengyang Zhou
Frontiers in Oncology.2022;[Epub] CrossRef - Anatomical Distribution of Colon Cancer: A Retrospective 10-Year Study to Evaluate Rightward Shift in Two Referral Hospitals in Iran
Ahmad R Mafi, Shima Azimi Oliaei, Ramin Heshmat, Hossein Yahyazadeh, Ali G Motlagh
International Journal of Cancer Management.2022;[Epub] CrossRef - Current status on microsatellite instability, prognosis and adjuvant therapy in colon cancer: A nationwide survey of medical oncologists, colorectal surgeons and gastrointestinal pathologists
James W. T. Toh, Hema Mahajan, Pierre Chapuis, Kevin Spring
Cancer Reports.2021;[Epub] CrossRef - Rate of dissemination and prognosis in early and advanced stage colorectal cancer based on microsatellite instability status: systematic review and meta-analysis
James W. T. Toh, Kevin Phan, Faizur Reza, Pierre Chapuis, Kevin J. Spring
International Journal of Colorectal Disease.2021; 36(8): 1573. CrossRef - Computed Tomography-Based Radiomics Model to Preoperatively Predict Microsatellite Instability Status in Colorectal Cancer: A Multicenter Study
Zhi Li, Qi Zhong, Liang Zhang, Minhong Wang, Wenbo Xiao, Feng Cui, Fang Yu, Chencui Huang, Zhan Feng
Frontiers in Oncology.2021;[Epub] CrossRef - Colon cancer patients with mismatch repair deficiency are more likely to present as acute surgical cases
Ioannis Gkekas, Jan Novotny, Tuomas Kaprio, Ines Beilmann-Lehtonen, Pavel Fabian, Sofia Edin, Karin Strigård, Tomas Svoboda, Jaana Hagström, Lucie Barsova, Tomas Jirasek, Caj Haglund, Richard Palmqvist, Ulf Gunnarsson
European Journal of Cancer.2021; 157: 1. CrossRef - Pathological Features and Prognostication in Colorectal Cancer
Kabytto Chen, Geoffrey Collins, Henry Wang, James Wei Tatt Toh
Current Oncology.2021; 28(6): 5356. CrossRef - Prognostic and predictive role of DNA mismatch repair status in stage II‐III colorectal cancer: A systematic review and meta‐analysis
Zhujun Deng, Yun Qin, Jing Wang, Gang Wang, Xiaoqiang Lang, Juan Jiang, Kang Xie, Wengeng Zhang, Heng Xu, Yang Shu, Yan Zhang
Clinical Genetics.2020; 97(1): 25. CrossRef Implication of Microsatellite Instability in Chinese Cohort of Human Cancers
Meiying Cui, Pan Li, Ying Mao, Lan Zhang, Peiyi Xia, Enjie Liu, Weiwei Wang, Jianying Zhang, Guozhong Jiang, Wencai Li
Cancer Management and Research.2020; Volume 12: 10287. CrossRef- Small RNA expression from viruses, bacteria and human miRNAs in colon cancer tissue and its association with microsatellite instability and tumor location
Robin Mjelle, Wenche Sjursen, Liv Thommesen, Pål Sætrom, Eva Hofsli
BMC Cancer.2019;[Epub] CrossRef - Evaluation of Long-Term Outcomes of Microsatellite Instability Status in an Asian Cohort of Sporadic Colorectal Cancers
Winson Jianhong Tan, Julie Liana Hamzah, Sanchalika Acharyya, Fung Joon Foo, Kiat Hon Lim, Iain Bee Huat Tan, Choong Leong Tang, Min Hoe Chew
Journal of Gastrointestinal Cancer.2018; 49(3): 311. CrossRef - Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system
Jeong Mo Bae, Jung Ho Kim, Yoonjin Kwak, Dae-Won Lee, Yongjun Cha, Xianyu Wen, Tae Hun Lee, Nam-Yun Cho, Seung-Yong Jeong, Kyu Joo Park, Sae Won Han, Hye Seung Lee, Tae-You Kim, Gyeong Hoon Kang
British Journal of Cancer.2017; 116(8): 1012. CrossRef - Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer
Li Li, Bei-Bei Ni, Qing-Hua Zhong, Yan-Hui Liu, Ming-Hui Zhang, Ke-Ping Zhang, Dai-Ci Chen, Lei Wang
Future Oncology.2017; 13(17): 1473. CrossRef - Comparison of oncological outcomes of right-sided colon cancer versus left-sided colon cancer after curative resection
Dae Ro Lim, Jung Kul Kuk, Taehyung Kim, Eung Jin Shin
Medicine.2017; 96(42): e8241. CrossRef - Downregulation of acetyl-CoA synthetase 2 is a metabolic hallmark of tumor progression and aggressiveness in colorectal carcinoma
Jeong Mo Bae, Jung Ho Kim, Hyeon Jeong Oh, Hye Eun Park, Tae Hun Lee, Nam-Yun Cho, Gyeong Hoon Kang
Modern Pathology.2017; 30(2): 267. CrossRef - Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study
Francesco Iachetta, Federica Domati, Luca Reggiani-Bonetti, Valeria Barresi, Giulia Magnani, Luigi Marcheselli, Claudia Cirilli, Monica Pedroni
Internal and Emergency Medicine.2016; 11(1): 41. CrossRef - Clinical, histological, and molecular risk factors for cancer recurrence in patients with stage II colon cancer
Yann Touchefeu, Marie Provost-Dewitte, Thierry Lecomte, Alain Morel, Isabelle Valo, Jean-François Mosnier, Céline Bossard, Juliette Eugène, Emilie Duchalais, Jérôme Chetritt, Serge Guyetant, Stéphane Bézieau, Hélène Senellart, Morgane Caulet, Estelle Cauc
European Journal of Gastroenterology & Hepatology.2016; 28(12): 1394. CrossRef - Microsatellite instability is associated with reduced disease specific survival in stage III colon cancer
H.M. Mohan, E. Ryan, I. Balasubramanian, R. Kennelly, R. Geraghty, F. Sclafani, D. Fennelly, R. McDermott, E.J. Ryan, D. O'Donoghue, J.M.P. Hyland, S.T. Martin, P.R. O'Connell, D. Gibbons, Des Winter, K. Sheahan
European Journal of Surgical Oncology (EJSO).2016; 42(11): 1680. CrossRef - Different treatment strategies and molecular features between right-sided and left-sided colon cancers
Hong Shen
World Journal of Gastroenterology.2015; 21(21): 6470. CrossRef - Is a Microsatellite Instability Still Useful for Tailored Treatment in Stage II and III Colon Cancer?
Nam Kyu Kim
Annals of Coloproctology.2014; 30(1): 5. CrossRef
- Microsatellite instability–high status enhances lymph node yield and reduces optimal dissection thresholds in colorectal cancer: A retrospective cohort analysis with β-binomial modeling
- Optimal Time of Initiating Adjuvant Chemotherapy After Curative Surgery in Colorectal Cancer Patients
- Kyu Min Kang, Kyung Sook Hong, Gyoung Tae Noh, Bo-Young Oh, Soon Sup Chung, Ryung-Ah Lee, Kwang Ho Kim
- Ann Coloproctol. 2013;29(4):150-154. Published online August 29, 2013
- DOI: https://doi.org/10.3393/ac.2013.29.4.150
- 8,446 View
- 41 Download
- 14 Citations
-
Abstract
PDF
Purpose Adjuvant chemotherapy is routinely recommended for locally advanced colorectal cancer (CRC). There are very few data for the optimal starting date of adjuvant chemotherapy after the surgery. This study aimed to evaluate the effectiveness of earlier adoption of adjuvant chemotherapy after curative surgery for stage III CRC.
Methods In this study, 159 patients with stage III CRC, who had undergone a curative resection, were enrolled retrospectively. Patients were categorized into 3 groups representing different timings to initiate the chemotherapy; less than 2 weeks (group 1), 3 to 4 weeks (group 2), and more than 5 weeks (group 3). The overall survival rate (OS) and the relapse-free survival rate (RFS) were analyzed to evaluate the effectiveness of adjuvant chemotherapy.
Results The 5-year OSs of the patients were 73.7% in group 1, 67.0% in group 2, and 55.2% in group 3. The 5-year RFSs of the patients were 48.8% in group 1, 64.7% in group 2, and 57.1% in group 3. There were no significant differences in either the OS or the RFS (P = 0.200, P = 0.405).
Conclusion Starting chemotherapy earlier than 6 weeks after surgery does not show any significant difference. Thus, although adjuvant chemotherapy should preferably begin within 6 weeks, the starting date should not necessarily be hastened, and the patient's general condition should be taken into consideration.
-
Citations
Citations to this article as recorded by- Optimal timing of cancer treatments: a call for emerging evidence from clinical trials and real-world studies
Jianrong Zhang, Rebecca Venchiarutti, Xiaofei Wang, Qihua He
British Journal of Cancer.2025; 132(12): 1085. CrossRef - Minimally Invasive Approach Provides Oncological Benefit in Patients with High Risk of Very Early Recurrence (VER) After Surgery for Intrahepatic Cholangiocarcinoma (iCCA)
Francesca Ratti, Cecilia Maina, Lucrezia Clocchiatti, Rebecca Marino, Federica Pedica, Andrea Casadei Gardini, Francesco De Cobelli, Luca Antonio Maria Aldrighetti
Annals of Surgical Oncology.2024; 31(4): 2557. CrossRef - The optimal time of starting adjuvant chemotherapy after curative surgery in patients with colorectal cancer
Yuchong Yang, Yao Lu, Hui Tan, Ming Bai, Xia Wang, Shaohua Ge, Tao Ning, Le Zhang, Jingjing Duan, Yansha Sun, Rui Liu, Hongli Li, Yi Ba, Ting Deng
BMC Cancer.2023;[Epub] CrossRef - Apurinic/apyrimidinic endonuclease 1 is associated with poor prognosis after curative resection followed by adjuvant chemotherapy in patients with stage III colon cancer
Ji Hyeong Song, Myung Sun Lee, Eun Young Cha, Kyung Ha Lee, Ji Yeon Kim, Jin Soo Kim
Korean Journal of Clinical Oncology.2022; 18(1): 1. CrossRef - Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
Hao Lin, Wen-Hsin Chen, Chen-Hsuan Wu, Yu-Che Ou, Yu-Jen Chen, Ying-Yi Chen, Yu-Han Lin, Hung-Chun Fu
Cancer Management and Research.2021; Volume 13: 5413. CrossRef - Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis
Sara Kaveh, Parvin Ebrahimi, Aziz Rezapour, Masoud Mozafari, Kourosh Sayehmiri
International Journal of Clinical Pharmacy.2019; 41(1): 30. CrossRef - Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis
Fausto Petrelli, Alberto Zaniboni, Antonio Ghidini, Michele Ghidini, Luca Turati, Claudio Pizzo, Margherita Ratti, Michela Libertini, Gianluca Tomasello
Cancers.2019; 11(4): 550. CrossRef - Safety and feasibility of in-hospital early chemotherapy initiation after surgery in patients with stage II–IV colon cancer
Jeonghyun Kang, Su-Weon Chong, Eun Jung Park, Seung Hyuk Baik, Kang Young Lee
Medicine.2019; 98(18): e15371. CrossRef - Surgical stress response and promotion of metastasis in colorectal cancer: a complex and heterogeneous process
Corina Behrenbruch, Carolyn Shembrey, Sophie Paquet-Fifield, Christina Mølck, Hyun-Jung Cho, Michael Michael, Benjamin N. J. Thomson, Alexander G. Heriot, Frédéric Hollande
Clinical & Experimental Metastasis.2018; 35(4): 333. CrossRef - Intensity modulated radiotherapy delivers competitive local control rate with limited acute toxicity in the adjuvant treatment of rectal cancer
Cheng-Yen Lee, Chih-Chia Chang, Hsin-Yi Yang, Pin-Yi Chiang, Yuk-Wah Tsang
Japanese Journal of Clinical Oncology.2018; 48(7): 653. CrossRef - Molecular analysis of sentinel lymph node in colon carcinomas by one-step nucleic acid amplification (OSNA) reduces time to adjuvant chemotherapy interval
Alix Marhic, Jean-François Tremblay, Rachid Kaci, Thierry André, Clarisse Eveno, Marc Pocard
Digestive and Liver Disease.2017; 49(8): 924. CrossRef - Timely initiation of chemotherapy: a systematic literature review of six priority cancers – results and recommendations for clinical practice
M. Alexander, R. Blum, K. Burbury, J. Coutsouvelis, M. Dooley, O. Fazil, T. Griffiths, H. Ismail, S. Joshi, N. Love, S. Opat, P. Parente, N. Porter, E. Ross, J. Siderov, P. Thomas, S. White, S. Kirsa, D. Rischin
Internal Medicine Journal.2017; 47(1): 16. CrossRef - Association Between Time (Initiation and Length) and Oncological Outcomes for the Patients with Colon Cancer Treated with Adjuvant Chemotherapy
In Seob Jeong, Jong Han Yoo, Sang Hyuk Seo, Min Sung An, Kwang Hee Kim, Ki Beom Bae, Chang Soo Choi, Jin Won Hwang, Ji Hyun Kim, Mi Seon Kang, Min Kyung Oh, Kwan Hee Hong
Indian Journal of Surgery.2015; 77(S3): 1252. CrossRef - Timing of Adjuvant Chemotherapy in Colorectal Cancer Patients
Moo-Jun Baek
Annals of Coloproctology.2013; 29(4): 138. CrossRef
- Optimal timing of cancer treatments: a call for emerging evidence from clinical trials and real-world studies
Review
- The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer
- Young Wan Kim, Ik Yong Kim
- Ann Coloproctol. 2013;29(2):44-54. Published online April 30, 2013
- DOI: https://doi.org/10.3393/ac.2013.29.2.44
- 6,559 View
- 39 Download
- 29 Citations
-
Abstract
PDF
There are still debates regarding the appropriate primary treatment policy for asymptomatic primary colorectal lesions in cases of unresectable metastatic colorectal cancer. Even though there are patients with asymptomatic primary tumors when starting chemotherapy, those patients may still undergo surgery due to complications related to primary tumors in the middle of chemotherapy; therefore, controversy exists regarding surgical resection of primary colorectal lesions in cases where symptoms are absent when making a diagnosis. Thus, based on the published literature, we discuss opinions that prefer first-line surgery for primary tumors as well as opinions favoring first-line chemotherapy for treating unresectable synchronous metastatic colorectal cancer. Although the upfront chemotherapy including targeted agents is suggested as an effective treatment in recent years, the first line surgery has been a preferred treatment for decades. The first line surgery is beneficial to prolong the survival duration given the retrospective analysis of randomized trial data. So far, no prospective comparison study has only focused on the first-line treatment modality; thus, future clinical studies focusing on the survival duration and the quality of life should be performed as soon as possible. Furthermore, at this point, multidisciplinary team approaches would be helpful in finding the appropriate therapy. Regardless of symptoms, the performance status and the tumor burden should be taken into consideration as well. In case of surgical resection, minimally invasive surgery, such as laparoscopic surgery, is recommended.
-
Citations
Citations to this article as recorded by- Self-Expanding Metal Stents as an Alternative to Palliative Surgery in Advanced Obstructive Colorectal Cancer—A Systematic Review and Meta-Analysis
Vlad Rotaru, Elena Chitoran, Giuseppe Gullo, Daniela Viorica Mosoiu, Laurentiu Simion
Journal of Clinical Medicine.2025; 14(12): 4339. CrossRef - Randomized non-inferiority single-center prospective trial of malignant colonic obstruction therapy with Self-expandable metal stent (SEMS) endoscopic placement or stoma formation
I.E. Gorovaia, P.V. Tsarkov, P.V. Pavlov, I.A. Tulina, V.I. Zhurkovskiy
Endoscopic Surgery.2024; 30(2): 5. CrossRef - Fístula anastomótica y reingreso no programado al quirófano en cirugía oncológica colorrectal electiva: experiencia de un centro de alta complejidad
Diego Téllez, Daniela Yucuma, María Díaz, Saúl-Javier Rúgeles, Luis Jorge Lombana
Revista Mexicana de Coloproctología Enfermedades del Ano, Recto y Colon.2024; 20(1): 19. CrossRef - Palliative procedures for advanced obstructive colorectal cancer: a systematic review and meta-analysis
Bingqing Ma, Tianxing Ren, Chengjun Cai, Biao Chen, Jinxiang Zhang
International Journal of Colorectal Disease.2024;[Epub] CrossRef - Impact of primary tumor resection on the survival of patients with unresectable colon cancer liver metastasis at different colonic subsites: a propensity score matching analysis
Jiefeng Zhao, Jinfeng Zhu, Chao Huang, Rongfa Yuan, Zhengming Zhu
Acta Chirurgica Belgica.2023; 123(2): 132. CrossRef - Prognosis of patients with unresectable stage IV Colon cancer undergoing primary tumor resection: A multicenter study of minimally symptomatic or asymptomatic primary tumor
Man Fung Ho, Victoria Cindy Lai, Dennis Chung Kei Ng, Simon Siu Man Ng
Asian Journal of Surgery.2023; 46(9): 3710. CrossRef - Asymptomatic Primary Tumor Resection in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
Yefei Shu, Ling Xu, Wei Yang, Xiaofeng Xu, Song Zheng
Frontiers in Oncology.2022;[Epub] CrossRef - Pretreatment inflammatory markers predicting treatment outcomes in colorectal cancer
Sanghyun An, Hongjin Shim, Kwangmin Kim, Bora Kim, Hui-Jae Bang, Hyejin Do, Hyang-Rae Lee, Youngwan Kim
Annals of Coloproctology.2022; 38(2): 97. CrossRef - Stenting as a bridge to surgery for obstructed stage IV colorectal cancers – long‐term outcomes of a 10‐year study
Aik Yong Chok, Hui Jun Lim, Weng Kit Lye, Lasitha B Samarakoon, Jiwei Guo, Choong Leong Tang, Ronnie Mathew
Asian Journal of Endoscopic Surgery.2020; 13(3): 343. CrossRef - Frequency of unplanned surgery in patients with stage IV colorectal cancer receiving palliative chemotherapy with an intact primary: An analysis of SEER‐Medicare
Patrick D. Lorimer, Benjamin M. Motz, Russell C. Kirks, Yimei Han, James T. Symanowski, Jimmy J. Hwang, Jonathan C. Salo, Joshua S. Hill
Journal of Surgical Oncology.2019; 120(3): 407. CrossRef - The American Society of Anesthesiologists score influences on postoperative complications and total hospital charges after laparoscopic colorectal cancer surgery
Jae-Hyun Park, Dong-Hyun Kim, Bo-Ra Kim, Young-Wan Kim
Medicine.2018; 97(18): e0653. CrossRef - Identification of factors predictive of postoperative morbidity and short-term mortality in older patients after colorectal carcinoma resection: A single-center retrospective study
Teresa Schreckenbach, Matthias Valentin Zeller, Hanan El Youzouri, Wolf Otto Bechstein, Guido Woeste
Journal of Geriatric Oncology.2018; 9(6): 649. CrossRef - The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor
Qian-Kun Xie, Ping Chen, Wan-Ming Hu, Peng Sun, Wen-Zhuo He, Chang Jiang, Peng-Fei Kong, Shou-Sheng Liu, Hai-Tian Chen, Yuan-Zhong Yang, Dan Wang, Lin Yang, Liang-Ping Xia
Journal of Translational Medicine.2018;[Epub] CrossRef - Comparison of the Short-Term Outcomes of Laparoscopic and Open Resections for Colorectal Cancer in Patients with a History of Prior Median Laparotomy
Young Wan Kim, Ik Yong Kim
Indian Journal of Surgery.2017; 79(6): 527. CrossRef - A Novel Derivation Predicting Survival After Primary Tumor Resection in Stage IV Colorectal Cancer: Validation of a Prognostic Scoring Model and an Online Calculator to Provide Individualized Survival Estimation
Winson Jianhong Tan, Sreemanee Raaj Dorajoo, Madeline Yen Min Chee, Wah Siew Tan, Fung Joon Foo, Choong Leong Tang, Min Hoe Chew
Diseases of the Colon & Rectum.2017; 60(9): 895. CrossRef - Comparative effectiveness of chemotherapy vs resection of the primary tumour as the initial treatment in older patients with Stage IV colorectal cancer
H. B. Mehta, G. M. Vargas, D. Adhikari, F. Dimou, T. S. Riall
Colorectal Disease.2017;[Epub] CrossRef - Primary tumor resection in stage IV unresectable colorectal cancer: what has changed?
Michał Pędziwiatr, Magdalena Mizera, Jan Witowski, Piotr Major, Grzegorz Torbicz, Natalia Gajewska, Andrzej Budzyński
Medical Oncology.2017;[Epub] CrossRef - The influence of local therapy on the survival of patients with metastatic rectal cancer: a population-based, propensity-matched study
Chi-Hao Zhang, Yuan-Bo Pan, Qing-Wei Zhang, Ou-Min Shi, Lei Zheng, Liang Gui, Meng Luo
Journal of Cancer Research and Clinical Oncology.2017; 143(9): 1891. CrossRef - Primary tumor location as a predictor of the benefit of palliative resection for colorectal cancer with unresectable metastasis
Rong-xin Zhang, Wen-juan Ma, Yu-ting Gu, Tian-qi Zhang, Zhi-mei Huang, Zhen-hai Lu, Yang-kui Gu
World Journal of Surgical Oncology.2017;[Epub] CrossRef - The impact of delayed commencement of adjuvant chemotherapy (eight or more weeks) on survival in stage II and III colon cancer: a national population-based cohort study
Young Wan Kim, Eun Hee Choi, Bo Ra Kim, Woo-Ah Ko, Yeong-Mee Do, Ik Yong Kim
Oncotarget.2017; 8(45): 80061. CrossRef - Lymph node status as a prognostic factor after palliative resection of primary tumor for patients with metastatic colorectal cancer
Qingguo Li, Changjian Wang, Yaqi Li, Xinxiang Li, Ye Xu, Guoxiang Cai, Peng Lian, Sanjun Cai
Oncotarget.2017; 8(29): 48333. CrossRef - Long-term outcomes of palliation for unresectable colorectal cancer obstruction in patients with good performance status: endoscopic stent versus surgery
Hyo Jun Ahn, Sang Woo Kim, Sung Won Lee, Soon Wook Lee, Chul-Hyun Lim, Jin Su Kim, Yu Kyung Cho, Jae Myung Park, In Seok Lee, Myung-Gyu Choi
Surgical Endoscopy.2016; 30(11): 4765. CrossRef - Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer
Hugh Colvin, Naohiro Nishida, Masamitsu Konno, Naotsugu Haraguchi, Hidekazu Takahashi, Junichi Nishimura, Taishi Hata, Koichi Kawamoto, Ayumu Asai, Kenta Tsunekuni, Jun Koseki, Tsunekazu Mizushima, Taroh Satoh, Yuichiro Doki, Masaki Mori, Hideshi Ishii
Scientific Reports.2016;[Epub] CrossRef - A scoring model for predicting survival following primary tumour resection in stage IV colorectal cancer patients with unresectable metastasis
S. R. Dorajoo, W. J. H. Tan, S. X. Koo, W. S. Tan, M. H. Chew, C. L. Tang, H. L. Wee, C. W. Yap
International Journal of Colorectal Disease.2016; 31(2): 235. CrossRef - Factors Affecting Use and Delay (≥8 Weeks) of Adjuvant Chemotherapy after Colorectal Cancer Surgery and the Impact of Chemotherapy-Use and Delay on Oncologic Outcomes
Ik Yong Kim, Bo Ra Kim, Young Wan Kim, Ramon Andrade de Mello
PLOS ONE.2015; 10(9): e0138720. CrossRef - The Role of Palliative Resection for Asymptomatic Primary Tumor in Patients With Unresectable Stage IV Colorectal Cancer
Jung-A Yun, Jung Wook Huh, Yoon Ah Park, Yong Beom Cho, Seong Hyeon Yun, Hee Cheol Kim, Woo Yong Lee, Ho-Kyung Chun
Diseases of the Colon & Rectum.2014; 57(9): 1049. CrossRef - A Meta-Analysis to Determine the Effect of Primary Tumor Resection for Stage IV Colorectal Cancer with Unresectable Metastases on Patient Survival
Cillian Clancy, John P. Burke, Mitchel Barry, Matthew F. Kalady, J. Calvin Coffey
Annals of Surgical Oncology.2014; 21(12): 3900. CrossRef - Association Between Palliative Resection of the Primary Tumor and Overall Survival in a Population-Based Cohort of Metastatic Colorectal Cancer Patients
Gillian Gresham, Daniel J. Renouf, Matthew Chan, Hagen F. Kennecke, Howard J. Lim, Carl Brown, Winson Y. Cheung
Annals of Surgical Oncology.2014; 21(12): 3917. CrossRef - Risk factors for the requirement of surgical or endoscopic interventions during chemotherapy in patients with uncomplicated colorectal cancer and unresectable synchronous metastases
Jung-A Yun, Yoonah Park, Jung Wook Huh, Yong Beom Cho, Seong Hyeon Yun, Hee Cheol Kim, Woo Yong Lee, Ho-Kyung Chun
Journal of Surgical Oncology.2014; 110(7): 839. CrossRef
- Self-Expanding Metal Stents as an Alternative to Palliative Surgery in Advanced Obstructive Colorectal Cancer—A Systematic Review and Meta-Analysis
Original Article
- Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer
- Sun Hee Jee, Sun Mi Moon, Ui Sup Shin, Hoe Min Yang, Dae-Yong Hwang
- J Korean Soc Coloproctol. 2011;27(6):322-328. Published online December 31, 2011
- DOI: https://doi.org/10.3393/jksc.2011.27.6.322
- 6,935 View
- 37 Download
- 18 Citations
-
Abstract
PDF
Purpose The aims of this study were to investigate the survival results and the prognostic factors of adjuvant chemotherapy in stage II colon cancer in the sparsity of Korean data.
Methods From 1993 to 2006, 363 curatively resected pathologic stage II colon cancer patients were enrolled. Six cycles of adjuvant chemotherapy was performed: intravenous bolus 5-fluorouracil (5-FU) 500 mg/m2 with leucovorin 20 mg/m2 for 2 hours daily for 5 days, followed by a 3-week resting period (n = 308). Fifty-five patients received only curative surgery. A high risk of recurrence was defined as the presence of one or more of the following factors: T4 tumor, lympho-vascular invasion, perineural invasion, perforation, obstruction, retrieved lymph node < 12, and poorly differention. The median follow-up period was 68 months (1 to 205 months).
Results The five-year overall survival (OS) rate was 90.1%, and the five-year disease-free survival (DFS) rate was 84.7%. Among high-risk patients, the OS and the DFS rates of the treatment group were significantly higher than those of the non-treatment group (OS: 90.6% vs. 69.1%, P < 0.0001; DFS: 85.9% vs. 54.1%, P < 0.0001). Among low-risk patients, the survival results of the treatment group were also significantly superior (OS: 97.7% vs. 88.2%, P < 0.0001; DFS: 93.0% vs. 80.0%, P = 0.001). In the multivariate analysis, adjuvant chemotherapy was a significantly favorable prognostic factor for overall survival (hazard ratio, 0.41; 95% confidence interval, 0.22 to 0.75; P = 0.004).
Conclusion In our population, adjuvant chemotherapy showed superior survival to curative surgery alone and significantly reduced the risk of death. A nationwide multicenter randomized trial is needed.
-
Citations
Citations to this article as recorded by- Novel Drug Combinations in Lung Cancer: New Potential Synergies Between 5-FU and Repurposed Drugs
Eduarda Ribeiro, Nuno Vale
Applied Sciences.2024; 14(21): 9658. CrossRef - Ulva pertusa Modulated Colonic Oxidative Stress Markers and Clinical Parameters: A Potential Adjuvant Therapy to Manage Side Effects During 5-FU Regimen
Alberto Repici, Anna Paola Capra, Ahmed Hasan, Rossella Basilotta, Sarah Adriana Scuderi, Michela Campolo, Irene Paterniti, Emanuela Esposito, Alessio Ardizzone
International Journal of Molecular Sciences.2024; 25(23): 12988. CrossRef - Using zebrafish to assess the effect of chronic, early developmental exposure to environmentally relevant concentrations of 5-fluorouracil and leucovorin
M. Ng, K. DeCicco-Skinner, V.P. Connaughton
Environmental Toxicology and Pharmacology.2020; 76: 103356. CrossRef - Postoperative chemotherapy improves survival in patients with resected high‐risk Stage II colorectal cancer: results of a systematic review and meta‐analysis
C. Simillis, H. K. S. I. Singh, T. Afxentiou, S. Mills, O. J. Warren, J. J. Smith, P. Riddle, M. Adamina, D. Cunningham, P. P. Tekkis
Colorectal Disease.2020; 22(10): 1231. CrossRef - Patient Selection for Adjuvant Chemotherapy in High-Risk Stage II Colon Cancer
Chao Zhang, Songcheng Yin, Yuen Tan, Jinyu Huang, Pengliang Wang, Wenbin Hou, Zhe Zhang, Huimian Xu
American Journal of Clinical Oncology.2020; 43(4): 279. CrossRef - Scoulerine promotes cell viability reduction and apoptosis by activating ROS-dependent endoplasmic reticulum stress in colorectal cancer cells
Jiaxun Tian, Jiamei Mo, Lan Xu, Rui Zhang, Yun Qiao, Bin Liu, Lei Jiang, Siyang Ma, Gang Shi
Chemico-Biological Interactions.2020; 327: 109184. CrossRef - Effectiveness of adjuvant chemotherapy in patients with Stage II colorectal cancer: A multicenter retrospective study
Hasan Jalaeikhoo, Mohammad Zokaasadi, Ahmad Khajeh-Mehrizi, Mohsen Rajaeinejad, Seied Asadollah Mousavi, Mohammad Vaezi, Hosein Kmranzadeh Fumani, Manoutchehr Keyhani, Kamran Alimoghaddam, Ardeshir Ghavamzadeh
Journal of Research in Medical Sciences.2019;[Epub] CrossRef - Colorectal obstruction is a potential prognostic factor for stage II colorectal cancer
Yusuke Okuda, Takaya Shimura, Tomonori Yamada, Yoshikazu Hirata, Ryuzo Yamaguchi, Eiji Sakamoto, Hiromi Kataoka
International Journal of Clinical Oncology.2018; 23(6): 1101. CrossRef - Effect of Adjuvant Chemotherapy on Stage II Colon Cancer: Analysis of Korean National Data
Min Ki Kim, Daeyoun David Won, Sun Min Park, Taejung Kim, Sung Ryong Kim, Seong Taek Oh, Seung Kook Sohn, Mi Yeon Kang, In Kyu Lee
Cancer Research and Treatment.2018; 50(4): 1149. CrossRef - Perineural Invasion Is a Strong Prognostic Factor in Colorectal Cancer
Nikki Knijn, Stephanie C. Mogk, Steven Teerenstra, Femke Simmer, Iris D. Nagtegaal
American Journal of Surgical Pathology.2016; 40(1): 103. CrossRef - Prognostic Value of Perineural Invasion in Colorectal Cancer: A Meta-Analysis
Yuchong Yang, Xuanzhang Huang, Jingxu Sun, Peng Gao, Yongxi Song, Xiaowan Chen, Junhua Zhao, Zhenning Wang
Journal of Gastrointestinal Surgery.2015; 19(6): 1113. CrossRef - Colchicine induces apoptosis in HT-29 human colon cancer cells via the AKT and c-Jun N-terminal kinase signaling pathways
ZHEN HUANG, YE XU, WEI PENG
Molecular Medicine Reports.2015; 12(4): 5939. CrossRef - Is Microsatellite Instability Really a Good Prognostic Factor of Colorectal Cancer?
Ui Sup Shin, Sang Sik Cho, Sun Mi Moon, Sun Hoo Park, Sun Hee Jee, Eun-Joo Jung, Dae-Yong Hwang
Annals of Coloproctology.2014; 30(1): 28. CrossRef - The Sirtuin 3 Expression Profile Is Associated with Pathological and Clinical Outcomes in Colon Cancer Patients
Chunyuan Liu, Zonghai Huang, Hong Jiang, Fujun Shi
BioMed Research International.2014; 2014: 1. CrossRef - Do High-risk Features Support the Use of Adjuvant Chemotherapy in Stage II Colon Cancer? A Turkish Oncology Group Study
Mehmet Artac, Nazim Serdar Turhal, Murat Kocer, Bulent Karabulut, Hakan Bozcuk, Suayip Yalcin, Mustafa Karaagac, Seyda Gündüz, Nalan Isik, Kazim Uygun
Tumori Journal.2014; 100(2): 143. CrossRef - Laparoscopic Colectomy Decreases the Time to Administration of Chemotherapy Compared with Open Colectomy
Vitaliy Poylin, Thomas Curran, Eliza Lee, Deborah Nagle
Annals of Surgical Oncology.2014; 21(11): 3587. CrossRef - Identification of the Risk Factors for Recurrence of Stage II Rectal Cancer
Sho Sawazaki, Manabu Shiozawa, Teni Godai, Yusuke Katayama, Koji Numata, Akio Higuchi, Yasushi Rino, Munetaka Masuda, Makoto Akaike
Nippon Daicho Komonbyo Gakkai Zasshi.2014; 67(5): 305. CrossRef - Current Controversies in the Management of Colon Cancer
Supriya S. Patel, Adrienne Floyd, Michael G. Doorly, Adrian E. Ortega, Glenn T. Ault, Andreas M. Kaiser, Anthony J. Senagore
Current Problems in Surgery.2012; 49(7): 398. CrossRef
- Novel Drug Combinations in Lung Cancer: New Potential Synergies Between 5-FU and Repurposed Drugs
Review
- Colorectal Cancer with Multiple Metastases: Is Palliative Surgery Needed?
- Hong-Jo Choi, Jin Yong Shin
- J Korean Soc Coloproctol. 2011;27(5):226-230. Published online October 31, 2011
- DOI: https://doi.org/10.3393/jksc.2011.27.5.226
- 4,625 View
- 31 Download
- 1 Citations
-
Abstract
PDF
In patients with symptomatic incurable metastatic colorectal cancer (mCRC), the goal of resection of the primary lesion is to palliate cancer-related morbidity, including obstruction, bleeding, or perforation. In patients with asymptomatic primary tumors and incurable metastatic disease, however, the necessity of primary tumor resection is less clear. Although several retrospective analyses suggest survival benefit in patients who undergo resection of the primary tumor, applying this older evidence to modern patients is out of date for several reasons. Modern chemotherapy regimens incorporating the novel cytotoxic agents oxaliplatin and irinotecan, as well as the target agents bevacizumab and cetuximab, have improved median survival from less than 1 year with the only available single-agent 5-fluorouracil until the mid-1990s to over 2 years. In addition to significant prolongation of overall survival, combinations of novel chemotherapeutic and target agents have allowed improved local and distant tumor control, decreasing the likelihood of local tumor-related complications requiring surgical resection. Resection of an asymptomatic primary tumor risks surgical complications and may postpone the administration of chemotherapy that may offer both systemic and local control. In conclusion, the morbidity and the mortality of unnecessary surgery or surgery that does not improve quality of life or survival in patients with mCRC of a limited life expectancy should be carefully evaluated. With the availability of effective combinations of chemotherapy and target agents, systemic therapy for the treatment of life-threatening metastases would be a preferable treatment strategy for unresectable asymptomatic patients with mCRC.
-
Citations
Citations to this article as recorded by- Palliative laparoscopic bowel resection in stage IV colorectal cancer patients with unresectable metastasis
Kwan Mo Yang, Seok-Byung Lim, Yong Sik Yoon, Chan Wook Kim, In Ja Park, Chang Sik Yu, Jin Cheon Kim
Korean Journal of Clinical Oncology.2013; 9(2): 134. CrossRef
- Palliative laparoscopic bowel resection in stage IV colorectal cancer patients with unresectable metastasis
Original Articles
- Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
- Hyeong-Joon Jeon, Jin-Hee Woo, Hak-Yoon Lee, Ki-Jae Park, Hong-Jo Choi
- J Korean Soc Coloproctol. 2011;27(3):140-146. Published online June 30, 2011
- DOI: https://doi.org/10.3393/jksc.2011.27.3.140
- 11,371 View
- 59 Download
- 12 Citations
-
Abstract
PDF
Purpose Great progress has been made in the adjuvant treatment of colon cancer. The aim of this study was to evaluate the efficacy of postoperative adjuvant chemotherapy using the FOLFOX regimen in patients with stage III and high-risk stage II colon cancer.
Methods Eighty-two patients who underwent a potentially curative resection for stage III or high-risk stage II colon cancer were enrolled in this retrospective study. They received FOLFOX4 or modified FOLFOX6. The primary endpoint was disease-free survival.
Results During the median follow-up of 37 months (range, 21 to 61 months), 14 patients experienced disease relapse. The disease-free survival rate at 3 years was 82.9%: 84.6% for stage II and 82.6% for stage III. At the time of the analysis, 8 patients were dead from recurrence. The probability of overall survival at 5 years was 74.5%: 90% for stage II and 74.6% for stage III. Grade 3 or 4 hematologic adverse events included neutropenia (40.2%), anemia (2.4%), and thrombocytopenia (1.2%). Gastrointestinal toxicities included grade 3 or 4 nausea (4.9%) and stomatitis (2.4%). Peripheral sensory neuropathy was observed in 81.7% of the patients during treatment. Of the 11 patients (13.4%) who had grade 3 peripheral sensory neuropathy during treatment, grade 3 symptoms were persistent in 3 patients with gait disturbance at the time of analysis. No treatment-related deaths were recorded.
Conclusion Postoperative chemotherapy using the FOLFOX regimen, oxaliplatin in combination with 5-fluorouracil and leucovorin, is effective and tolerable in patients with stage III and high-risk stage II colon cancer.
-
Citations
Citations to this article as recorded by- Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries
Bazarbashi Shouki, Alnajjar Abdelsalam, Al Sharm Abdullah, Alshammari Kanan, Al Sherhi Ahmed, Dawoud Emad, Heinemann Volker, Aseafan Mohamed, Chehal Aref, Alghamdi Mohammed, Hamza Dina, Khoury Maroun, Venniyoor Ajit, Mahrous Mervat, Rasul Kakil, Elsamany
Therapeutic Advances in Medical Oncology.2025;[Epub] CrossRef - Cathayanon E induces apoptosis and enhances oxaliplatin sensitivity in colorectal cancer through suppression of MCL1
Liang Cen, Xin Hu, Guozhen An, Lichao Wang, Yanghao Hu, Junjie He, Hanghang Qin, Yongsen Li, Hongjuan Cui
Apoptosis.2025;[Epub] CrossRef - Transcriptomic and Cytogenetic Analysis of Oxaliplatin-Resistant Colorectal Adenocarcinoma HCT116 Cells to Identify Markers Associated with Platinum Resistance
Alisa Morshneva, Olga Gnedina, Ksenia Fedotova, Natalija Yartseva, Nikolay Aksenov, Maria Igotti
International Journal of Molecular Sciences.2025; 26(18): 8869. CrossRef - Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
Shirin Kianersi, Sina Salari, Hamid Rezvani, Mohammad A. Araskhan, Alireza Shirangi, Mohammad R. Fathi, Mahmoud D. Ghorbi
Journal of Education and Health Promotion.2023;[Epub] CrossRef - Extending the boundaries of cancer therapeutic complexity with literature text mining
Danna Niezni, Hillel Taub-Tabib, Yuval Harris, Hagit Sason, Yakir Amrusi, Dana Meron-Azagury, Maytal Avrashami, Shaked Launer-Wachs, Jon Borchardt, M. Kusold, Aryeh Tiktinsky, Tom Hope, Yoav Goldberg, Yosi Shamay
Artificial Intelligence in Medicine.2023; 145: 102681. CrossRef - Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer
T. Quang Nguyen, T. Oanh Bui, P. Thao Tran, V. Thuan Tran, V. Hieu Nguyen, Q. Hoan Chu, T. A. Tuyet Bui, N. Quynh Le, V. Quang Le, V. Tu Dao
Cancer Control.2019;[Epub] CrossRef - Operative Versus Nonoperative Management of Appendicitis: A Long-Term Cost Effectiveness Analysis
Lindsay A. Sceats, Seul Ku, Alanna Coughran, Britainy Barnes, Emily Grimm, Matthew Muffly, David A. Spain, Cindy Kin, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert
MDM Policy & Practice.2019;[Epub] CrossRef - Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer
Shelby N. Bess, Gage J. Greening, Timothy J. Muldoon
Cytokine & Growth Factor Reviews.2019; 49: 1. CrossRef - Association of baseline patient characteristics with adjuvant chemotherapy toxicities in stage III colorectal cancer patients
Akie Watanabe, Chang Cheng Yang, Winson Y. Cheung
Medical Oncology.2018;[Epub] CrossRef - Risk Stratification in Patients with Stage II Colon Cancer
Ramzi Amri, Jonathan England, Liliana G. Bordeianou, David L. Berger
Annals of Surgical Oncology.2016; 23(12): 3907. CrossRef - Anti-Colorectal Cancer Chemotherapy-Induced Diarrhoea: Current Treatments and Side-Effects
Rachel M. McQuade, Joel C. Bornstein, Kulmira Nurgali
International Journal of Clinical Medicine.2014; 05(07): 393. CrossRef - Multiple Cancers in a Patient with Systemic Sclerosis and Aggravated Interstitial Lung Disease by Chemotherapy
Chan Kwon Park, Seok Jong Lee, Hyung Jun Cho, Kyeong Soo Lee, Sung Jun Kim, Gu Min Cho, Ha Ni Lee
Tuberculosis and Respiratory Diseases.2013; 75(3): 111. CrossRef
- Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries
- Intraoperative Radiotherapy for Locally Advanced Rectal Cancer
- Min Kyu Kang, Myung Se Kim, Jae Hwang Kim
- J Korean Soc Coloproctol. 2010;26(4):274-278. Published online August 31, 2010
- DOI: https://doi.org/10.3393/jksc.2010.26.4.274
- 4,405 View
- 30 Download
- 3 Citations
-
Abstract
PDF
Purpose Although intraoperative radiotherapy (IORT) is known to be a method that can reduce local recurrence in locally advanced colorectal cancer, it is not widely used. The aim of this study was to report our experience with IORT for locally advanced rectal cancer.
Methods From 1991 to 1994, nine patients with locally advanced rectal cancer received IORT. External beam radiotherapy was given postoperatively in five patients and preoperatively in three. Seven patients received chemotherapy. IORT was done with 6-MeV or 9-MeV electrons, and 12 Gy was irradiated at the tumor bed. The median follow-up period was 84 months (range, 15 to 208 months).
Results The median age of patients was 51 years (range, 42 to 73 years). All patients had advanced clinical T-stage (cT3/4) cancer. The overall and the disease-free survival rates were 66.7% and 66.7% at 5 years, respectively. One patient developed a local recurrence near the anastomosis site, which was out of the IORT field. Four patients died before the last follow-up; three from distant metastasis and one from secondary primary cancer. Adverse effects related to IORT did not occur.
Conclusion Although the number of patients was small in this study, IORT is thought to be safe and effective in reducing local recurrence in locally advanced rectal cancer. However, the role of IORT should be refined in the era of preoperative radio-chemotherapy followed by total mesorectal excision.
-
Citations
Citations to this article as recorded by- Laparoscopic abdominoperineal resection with intraoperative radiotherapy for locally advanced low rectal cancer
Matej Skrovina, Renata Soumarova, Miloslav Duda, Roman Bezdek, Jiri Bartos, Adam Wendrinski, Petr Andel, Javed Parvez, Martin Straka, Lukas Adamcik
Biomedical Papers.2014; 158(3): 447. CrossRef - Laparoscopic Resection with Intraoperative Radiotherapy for Local Advanced Rectal Cancer: A Preliminary Case Report
Yimei Jiang, Xiaopin Ji, Shengguang Zhao, Ren Zhao, Yening Jin
Journal of Laparoendoscopic & Advanced Surgical Techniques.2013; 23(3): 267. CrossRef - A review of the logistic role of l‐carnitine in the management of radiation toxicity and radiotherapy side effects
Haseeb Ahmad Khan, Abdullah Saleh Alhomida
Journal of Applied Toxicology.2011; 31(8): 707. CrossRef
- Laparoscopic abdominoperineal resection with intraoperative radiotherapy for locally advanced low rectal cancer
- Invasiveness of and Drug Sensitivity to Various Anti-cancer Regimens in Five Colorectal Cancer Cell Lines.
- Lee, Yoo Mi , Yoon, Yong Sik , Roh, Seon Ae , Cho, Dong Hyung , Kim, Jin Cheon
- J Korean Soc Coloproctol. 2010;26(2):98-104.
- DOI: https://doi.org/10.3393/jksc.2010.26.2.98
- 2,105 View
- 13 Download
- 1 Citations
-
Abstract
PDF
- PURPOSE
Colorectal cancer (CRC) is one of the leading causes of cancer death in South Korea. Angiogenesis has been associated with invasion and metastasis of tumors and with the secretion of various growth factors. Bevacizumab is a humanized monoclonal antibody that recognizes and blocks vascular endothelial growth factor (VEGF) and that targets integrin alphaVbeta3 and matrix metalloproteinases (MMPs) as angiogensis inhibitors. The aims of this study were identification of the mechanism of target molecules related to angiogenesis and demonstration of identifiable invasion by using chemotherapeutic regimens in vitro.
METHODS
The five colorectal cancer cell lines were treated with bevacizumab using standard or combined regimens. The expression of integrin alphaVbeta3 was detected and the investigation of apoptosis was done by using flow cytometry. The activations of MMP-2 and MMP-9 were measured by using gelatin zymography.
RESULTS
The apoptotic cell death was significantly increased for the combined regimens, especially for FOLFOX (5-FU, leucovorin, and oxaliplatin) with bevacizumab. Bevacizumab inhibited the expression of integrin alphaVbeta3 in the HT29 (59%), LoVo (67%), and SW480 (17%) cell lines, but did not in the AMC5 and the RKO cell lines. The activations of MMP-2 and MMP-9 were significantly reduced by treatment with bevacizumab in the HT29 and the LoVo cell lines. In the HT29 and the LoVo cell lines, thus, bevacizumab inhibited invasion and metastasis activity through down-regulation of integrin alphaVbeta3 and MMPs.
CONCLUSION
Our results provide biological evidence of potent angiogenic activity and indicate that angiogenesis is a complex process that involves multiple factors, including VEGF, integrin alphaVbeta3, and MMPs. -
Citations
Citations to this article as recorded by- RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions
Hossein Javid, Mahsa Akbari Oryani, Nastaran Rezagholinejad, Ali Esparham, Mahboubeh Tajaldini, Mehdi Karimi‐Shahri
Cancer Medicine.2024;[Epub] CrossRef
- RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions
- Safety of Early Chemotherapy after a Laparoscopic Colorectal Cancer Resection: A Case-Control Study.
- Shin, Seung Ho , Lee, Sun Il , Choi, Dong Jin , Woo, Si Uk , Kim, Jin , Min, Byung Wook , Moon, Hong Young , Kim, Seon Hahn
- J Korean Soc Coloproctol. 2009;25(6):429-436.
- DOI: https://doi.org/10.3393/jksc.2009.25.6.429
- 2,252 View
- 10 Download
-
Abstract
PDF
- PURPOSE
Since micrometastasis is generally inhibited by primary cancer, surgical ablation of the tumor may stimulate the growth of residual cancer cells, if they exist. This supports the importance of early administration of postoperative chemotherapy. METHODS: We reviewed the cases of patients who underwent a laparoscopic resection and then received chemotherapy (5 fluorouracil+leucovorin or FOLFOX4) between September 2006 and May 2008. The chemotherapy was scheduled on the 7th or the 8th postoperative day, but was postponed when a final pathologic report was delayed or patients were discharged early. The safety of chemotherapy was evaluated in two ways. Early safety, such as the presence of surgical complications and medical toxicity, was prospectively assessed just before the beginning of the second cycle of chemotherapy. Late safety, such as medical toxicity, was retrospectively estimated from the 2nd to the last cycle. These safeties were compared between the two groups: the early chemotherapy group (n=50) for which chemotherapy started on the 7th or 8th postoperative day as scheduled and the delayed chemotherapy group (n=31) for which chemotherapy started after the 14th postoperative day.
RESULTS
Patient demographics were not different between the two groups. With regards to early safety, no differences in surgical complications existed between the two groups. In medical toxicities, there were no differences, except for a higher rate of nausea in the early chemotherapy group (20 percent vs. 10 percent, P=0.01). With regards to late safety, the two groups were not different in the development of medical toxicities. CONCLUSION: Because nausea is an easily controllable toxicity, we conclude that chemotherapy is safely started on the 7th or the 8th day after a laparoscopic colorectal cancer resection.
Review
- Role of Radiation Therapy as an Adjuvant Treatment in Rectal Cancer Management.
- Oh, Jae Hwan , Kim, Dae Yong
- J Korean Soc Coloproctol. 2009;25(4):273-282.
- DOI: https://doi.org/10.3393/jksc.2009.25.4.273
- 2,091 View
- 9 Download
- 1 Citations
-
Abstract
PDF
- Surgical resection is a mainstay in the treatment for patients with locally advanced rectal cancer. Despite the introduction of total mesorectal excision, which greatly reduces local recurrence, radiation therapy and chemotherapy have prevailed as integral parts of the modern treatment concept. Phase III studies have shown that postoperative chemoradiotherapy (CRT) improves the local control and overall survival compared with surgery alone in treating patients with stage II, III rectal cancer. Recently, a prospective randomized study with a large sample size and long-term follow-up reported that preoperative CRT resulted in improved local control and sphincter preservation, reduced toxicities, and improved overall survival compared with postoperative CRT. The results of this study provide evidence for the use of preoperative CRT in the treatment of patients with clinical stage II and III rectal cancer. However, accurate pretreatment staging is required to minimize overtreatment and adverse effects.
-
Citations
Citations to this article as recorded by- An Update on Preoperative Radiotherapy for Locally Advanced Rectal Cancer
Seung-Gu Yeo, Dae Yong Kim
Journal of the Korean Society of Coloproctology.2012; 28(4): 179. CrossRef
- An Update on Preoperative Radiotherapy for Locally Advanced Rectal Cancer
Original Articles
- Mucinous Histology as a Predictive Marker of 5-Fluorouracil-based Adjuvant Chemotherapy for Colon Cancer.
- Kang, Jeonghyun , Min, Byung Soh , Park, Yoon Ah , Kim, Nam Kyu , Sohn, Seung Kook , Cho, Chang Hwan , Lee, Kang Young
- J Korean Soc Coloproctol. 2009;25(4):241-247.
- DOI: https://doi.org/10.3393/jksc.2009.25.4.241
- 2,652 View
- 17 Download
- 1 Citations
-
Abstract
PDF
- PURPOSE
The aim of this study was to evaluate the value of mucinous histology as a predictive marker of 5-Fluorouracil (FU)-based adjuvant chemotherapy in stage II, III colon cancer. METHODS: Between January 1995 and December 2004, 987 patients who underwent curative resections for stage II, III sporadic colon cancer were classified into two groups, a mucinous carcinoma (MC) group and a non-mucinous carcinoma (NMC) group, based on the histology of the primary tumor. The differences in their clinicopathological characteristics and the prognostic impact of 5-FU-based adjuvant chemotherapy for various tumor histologies were analyzed.
RESULTS
Of the 987 patients, MCs accounted for 6.8% (68 patients). MCs were more frequently located in the Rt. Colon (P<0.001) and were more frequently seen in young patients (less than 40 yr old) (P=0.028). The 5-yr survival rates between MC and NMC did not show any statistically significant difference. Patients, including both MC and NMC patients, who received 5-FU-based chemotherapy, revealed a better overall survival rate than patients with no adjuvant chemotherapy. In the multivariate analysis for the prognosis in NMC patients, 5-FU-based adjuvant chemotherapy, initial negative nodal status, and preoperative CEA <5 ng/mL were statistically significant prognostic factors (P values: <0.001, <0.001, and <0.001, respectively). In contrast, there was no statistically independent significance of 5-FU-based adjuvant chemotherapy in MC patients. CONCLUSION: In stage II and stage III sporadic colon cancer patients, response to 5-FU-based adjuvant chemotherapy in MC patients might be poor than it is in NMC patients. -
Citations
Citations to this article as recorded by- Early recurrence in patients undergoing curative surgery for colorectal cancer: is it a predictor for poor overall survival?
Jung Wook Huh, Chang Hyun Kim, Sang Woo Lim, Hyeong Rok Kim, Young Jin Kim
International Journal of Colorectal Disease.2013; 28(8): 1143. CrossRef
- Early recurrence in patients undergoing curative surgery for colorectal cancer: is it a predictor for poor overall survival?
- Preliminary Study of the Clinical Features of the Chemosensitivity Test in Colorectal Cancer.
- Park, Chan Sup , Choi, Sung Ho , Kim, Hung Dai
- J Korean Soc Coloproctol. 2007;23(5):358-364.
- DOI: https://doi.org/10.3393/jksc.2007.23.5.358
- 1,780 View
- 10 Download
-
Abstract
PDF
- PURPOSE
Colorectal cancers have been known to be refractory to chemotherapy in the past decades. Recently, novel agents have been developed and various data have shown an improved response rate and a survival benefit. However, considerable heterogeneity exists between cancers of the same tissue type, including colorectal cancer. Thus, Individualized chemotherapy that is tailored specifically to the characteristics of the tumor is necessary for an improved clinical outcome.
RESULTS
We evaluate the chemosensitivity of colorectal cancer to standard drugs (5-FU, oxaliplatin, and irinotecan) and to drugs used for other cancers (mitomycin, paclitaxel, and gemcitabine) by using Adenosine-triphosphate-based chemotherapy response assay (ATP-CRA).
RESULTS
The degree of in-vitro response to a single anticancer medication was highest for 5-FU. According to stages, 5-FU is the most sensitive chemotherapeutic agent in Duke's B, irinotecan in Duke's C, and 5-FU in Duke's D patients. With tumor location, irinotecan is most sensitive in colon cancers and 5-FU in rectal cancers. The effect of treatment is superior in the test-guided therapy group in Duke's D colorectal cancer patients.
CONCLUSIONS
Chemosensitivity tests may be useful in selecting optimum drugs for patient who require chemotherapy. However, the results of this study do not strongly support the usefulness of this assay; further studies with a sufficient number of cases and an extended observation period are ongoing.
- Effect of an Irinotencan, 5-Fluorouracil, and Leucovorin Combination Chemotherapy (FOLFIRI) in Metastatic Colorectal Cancer.
- Lee, Seung Hyun , Ahn, Byung Kwon , Baek, Sung Uhn
- J Korean Soc Coloproctol. 2007;23(5):333-337.
- DOI: https://doi.org/10.3393/jksc.2007.23.5.333
- 2,620 View
- 24 Download
- 1 Citations
-
Abstract
PDF
- PURPOSE
Irinotecan is a recently developed active agent in colorectal cancer. The combination of irinotecan and 5-fluorouracil (5-FU)/lecovorin (LV), known as the FOLFIRI regimen, has been approved for patients with metastatic colorectal cancer. The purpose of this study was to assess the efficacy and toxicity of the FOLFIRI regimen in the treatment of metastatic colorectal cancer.
METHODS
We reviewed the records of 65 patients who had received the FOLFIRI regimen from Jan. 2002 to Dec. 2005. The combination chemotherapy consisted of irinotecan (150~180 mg/m2 on day 1, 15) as a 2~6 hour infusion followed by bolus infusion of 5-FU (400 mg/m2) and continuous infusion of 5-FU (600 mg/m2 on days 1, 2, 15, 16), concurrently with LV (20 mg/m2 on day 1, 2, 15, 16) as a 2 hour infusion. Cycles were repeated in three-week intervals.
RESULTS
Of the 65 patients who had received the FOLFIRI regimen, 34 were male and 31 cases female. The median age was 54.4 years. The primary tumor sites were the colon in 29 cases (44.6%) and the rectum in 36 cases (56.4%). The metastatic sites were the liver in 33 cases (50.8%), the peritoneum in 21 (32.3%), the lung in 14 (21.5%), a lymph node in 4, and the pelvis in 2. Twenty-seven patients (41.5%) had received the combination chemotherapy as the first line. Of the patients who received more than 3 cycles, complete response was none. Partial responses were 3 (7.1%), stable disease status in 25 cases (59.5%) and progressive disease status in 14 cases (33.3%). The rate of progressive disease status for patients who had received FOLFIRI as the 2nd or the 3rd line were much higher than that of those who had received it as the 1st line chemotherapy. Early stops (<3 cycles) of chemotherapy were due to toxicity, such as nausea, as diarrhea, in 15 of 19 cases (78.9%).
CONCLUSIONS
The objective response rate of FOLFIRI was 7.1% in metastatic colorectal cancers. Nausea, vomiting, and diarrhea were the main causes of intolerance to the chemotherapy in most of the patients. -
Citations
Citations to this article as recorded by- Quality of Life in Colorectal Cancer Patients according to the Severity of Symptom Clusters Classification
Gyeonghui Jeong, Kyunghee Kim, Yeunhee Kwak
Asian Oncology Nursing.2014; 14(2): 74. CrossRef
- Quality of Life in Colorectal Cancer Patients according to the Severity of Symptom Clusters Classification
Reviews
- Treatment of Peritoneal Carcinomatosis from Colorectal Cancer.
- Kim, Hyung Jin , Oh, Seong Taek
- J Korean Soc Coloproctol. 2006;22(4):285-290.
- 1,310 View
- 5 Download
-
Abstract
PDF
- Intraperitoneal carcinomatosis accounts for 25~35% of recurrences of colorectal cancer, and peritoneal carcinomatosis from colorectal cancer has been regarded as a lethal condition. However, a combination of aggressive cytoreductive surgery and intraperitoneal chemotherapy has been tried and appears to be beneficial in selected patients. The primary goal of cytoreductive surgery is to remove all visible tumor within the peritoneal cavity. The goal of intraperitoneal chemotherapy is to eradicate the microscopic residual tumor and to prevent its recurrence. There are various ways to perform intraperitoneal chemotherapy. One is postoperative intraperitoneal chemotherapy, and another is intraoperative hyperthermic chemotherapy during surgery. Hyperthermia increases the penetration of chemotherapy into tissues and the level of chemotherapy cytotoxicity. The timing of surgery in cases of intraperitoneal chemotherapy and the optimal dosage of drugs must be evaluated in further studies. In colorectal cancer, the peritoneum should be regarded as an intra-abdominal organ, like the liver. Therefore, intraperitoneal carcinomatosis must be treated by using a combination of aggressive surgical treatment and intraperitoneal chemotherapy. Eventually, the long-term overall survival will be increased.
- Imrpoving Outcomes with Chemotherapy in Colorectal Cancer: Current Options, Current Evidence.
- Kim, Ik Yong
- J Korean Soc Coloproctol. 2006;22(2):137-149.
- 1,168 View
- 4 Download
-
Abstract
PDF
- The last several years have major advances in chemotherapy treatment for adjuvant and metastatic colorectal cancer. We've come from an overall survival of 6 months in patients treated with best supportive care in the mid 1980s and even in the early 1990s. The use of 5-FU/leucovorin alone generates an overall survival of about 6 months. The addition of irinotecan/oxaliplatin allows patients to live a median of about 15 to 17 months. If we make use of all 3 active drugs, FOLFOX and FOLFIRI in a sequential manner, we'll be able to generate an overall survival of about 20 months. Recently, the addition of molecular therapy, in particular bevacizumab and cetuximab to these cytotoxic drugs has allowed us to break the brick wall that was placed at about 2 years median overall survival in large phase 3 trials in patients with metastatic colorectal cancer. The recent presentations provided further evidence that the standard of care in the treatment of advanced CRC consists of a combination of highly active cytotoxic chemotherapy plus the addition of a biologic agents, For clinical research, investigation of the best therapy for CRC has clearly shifted away from investigating conventional chemotherapy toward the question of how to make best use of all available active agents, particularly the novel biologics. Randomized trials have also shown that preoperative chemoradiation yields higher rates of pathologic complete response and local control, compared with radiotherapy alone. In this article, I review recent trials on preoperative and adjuvant therapy of localized rectal cancer. The roles of newer agents, such as capecitabine, oxaliplatin, and bevacizumab, are also discussed, and other key issues in the treatment of localized rectal cancer are reviewed. The planned phase 3 first-line trial will continue to elucidate the role of the currently available biologics in the treatment of CRC. In this article, the important advances in optimal chemotherapy of colorectal cancer will be summarized and approaches to multidisciplinary treatment decision-making in both adjuvant and metastatic settings will be reviewd.
Case Report
- Neutropenic Enterocolitis after Chemotherapy for Colon Cancer.
- Chun, Jung Woo , Hong, Seong Woo , Chang, Yeo Goo , Lee, Hye Kyoung , Lee, Hyucksang
- J Korean Soc Coloproctol. 2006;22(1):62-65.
- 1,225 View
- 3 Download
-
Abstract
PDF
- Neutropenic enterocolitis is observed in approximately 10~46% of patients with acute leukemia, as well as in patients with other diseases, like acquired immunodeficiency syndrom (AIDS), that lead to profound neutropenia. Patients who become neutropenic after combined chemotherapy are at special risk of developing neutropenic enterocolitis. With the recently increasing numbers of patients with solid tumors treated with high-dose chemotherapy, the frequency of this disease is expected to increase. However, this disease has been rarely reported in patients with colon cancer treated with leucovorin and 5-fluorouracil for adjuvant chemotherapy. We report a case of neutropenic enterocolitis after a treatment of 5-fluorouracil and leucovorin for sigmoid colon cancer.
Clinical Trial
- Hematologic and Non-hematologic Toxicity after Intravenous Adjuvant 5-Fluorouracil and Leucovorin Treatment of Colorectal Cancer: A Prospective Study.
- Lee, Kyu Jae , Moon, Sun Mi , Hwang, Dae Yong
- J Korean Soc Coloproctol. 2005;21(6):426-432.
- 1,971 View
- 24 Download
-
Abstract
PDF
- PURPOSE
Although large clinical trials have been performed attempting to find an optimal 5-fluorouracil (5-FU)-based regimen on the basis of activity and toxicity, there have been few data reporting the toxicity. We experienced a less severe toxicity than previous reports, so we undertook an analysis of the toxicity profiles of 5-FU-based chemotherapy on colorectal cancer patients.
METHODS
Forty-two patients were consecutively enrolled in this study from Sep. 2002 to Sep. 2003. The primary endpoints were the incidences of anorexia, nausea, vomiting, diarrhea, constipation, headache, stomatitis, alopecia, and leukopenia, as recorded with the standard National Cancer Institute- Common Toxicity Criteria (NCI-CTC). The regimen used in this study was intravenous infusion of 5-FU, 500 mg/m2, plus leucovorin (LV), 20 mg, daily for 5 days every 4 weeks for 6 cycles. Information on toxic profiles was obtained by questionnaire and blood test data during each cycle of treatment.
RESULTS
Of the patients, 73.8% experienced at least one type of toxicity. There were no clinical grade 3/4 toxicities. Toxicites (grade 1/2) were as follows: anorexia (51.2%), nausea (50.4%), constipation (24.6%), headache (11.5%), vomiting (4.0%), diarrhea (2.4%), alopecia (2.0%), stomatitis (0.4%), and leukopenia (4.0%). The most common adverse event was gastrointestinal toxicity (16.6%). There were no deaths attributed to non-hematologic toxicity. There was no dose reduction during any cycle of treatment. In a comparison of the incidence of toxicity by age (<65 and > or =65), gender, and TNM stage, univariate analysis found no statistical differences.
CONCLUSIONS
Our data would seem to confirm that Korean patients experienced less incidence and severity of toxicity than Western patients. We believe that the accumulated data provide sufficient evidence that colorectal patients in Korea actually experience a less severe toxicity of 5-FU-based chemotherapy when they are treated on this schedule. Considering this study, a race-specific dose determination for a colorectal cancer adjuvant chemotherapeutic setting is warranted.
Original Articles
- Differences of Response Rates according to Metastatic Sites after Oxaliplatin, 5- Fluorouracil, and Leucovorin Combination Chemotherapy (FOLFOX 3) in Advanced Colorectal Cancer.
- Lee, Seung Hyun , Ahn, Byung Kwon , Baek, Sung Uhn
- J Korean Soc Coloproctol. 2005;21(1):42-47.
- 1,498 View
- 5 Download
-
Abstract
PDF
- PURPOSE
Oxaliplatin is a recently developed active agent in colorectal cancer. Clinical observations have demonstrated synergistic effects of oxaliplatin with 5-fluorouracil (5- FU) and leucovorin (LV), even in 5-FU-resistant colorectal cancer. The purpose of this study was to determine response rates according to clinical factors after oxaliplatin, 5-FU and LV combination chemotherapy (FOLFOX 3) in metastatic colorectal cancer.
METHODS
We reviewed 44 patients who had received FOLFOX 3 from Jan. 2000 to Dec. 2002. The combination chemotherapy consisted of oxaliplatin (85 mg/m2 on day 1) as a 2~6 hour infusion followed by continuous infusion of 5-FU (1500 mg/m2 on day 1, 2), concurrently with LV (45 mg on day 1, 2) as a 2 hour infusion. Cycles were repeated by 2-week intervals. We compared the response rates according to clinical factors such as primary sites, cycle, tumor differentiation, metastatic sites, serum CEA, and previous chemotherapy.
RESULTS
Of the 44 patients who had received the combination chemotherapy with oxaliplatin, 5-FU, and LV, 19 cases were male, 25 cases were female. The median age was 50.7 years. The primary tumor sites were colon in 21 cases (47.7%), and rectum in 23 cases (52.3%). The metastatic sites were liver in 27 cases (61.4%), lung in 9 (20.5%), pelvis in 3, lymph node in 5, and peritoneum in 1. Thirty- five patients had received the combination chemotherapy as first line. Complete response was observed in 3 cases (6.8%). Partial response was in 7 cases (15.9%), stable disease status in 15 cases (34.1%), progressive disease status in 19 cases (43.2%), respectively. There were a no significant differences in response rates according to primary sites, tumor differentiation, serum CEA, and previous chemotherapy. However, with the metastatic sites, there were significant differences in response rates. Response rates were higher in lung (5/9), lymph node (3/4) metastases than any other metastatic sites (P <0.01).
CONCLUSIONS
The objective response rate of FOLFOX 3 was 22.7% in metastatic colorectal cancers. The only significant clinical factor was metastatic sites. The lung and lymph node metastases showed better response than metastatses to liver, pelvis, and peritoneum. To evaluate the differences of response rates according to metastatic sites, we need further study.
- Clinicopathological Correlation of hMLH1 and hMSH2 Protein Expressions in Stage III Colon Cancer.
- Cho, Young Kyu , Yu, Chang Sik , Namgung, Hwan , Kim, Hee Chul , Kim, Jung Seon , Lee, Je Hwan , Kim, Tae Won , Kim, Jin C
- J Korean Soc Coloproctol. 2004;20(4):218-224.
- 1,160 View
- 3 Download
-
Abstract
PDF
- PURPOSE
Functional loss of mismatch repair has been reported to be the reason for resistance to several chemotherapeutic drugs. The expressions of hMLH1 and hMSH2 were examined to assess whether they correlated with the biological behavior and the chemotherapeutic responsiveness in paflents with sporadic colon cancers.
METHODS
Ninety-one patients with stage III primary colon cancer were included from the tumor registry of the Asan Medical Center, Seoul, Korea. All patients underwent a curative operation and postoperative chemotherapy with 5- fluorouracil and leucovorin for 6 cycles between 1993 and 1997. Immunohistochemical staining for hMLH1 and hMSH2 was performed using archival paraffin blocks. A positive expression was determined when unequivocal nuclear staining was identified in more than 10% of the cancer cells. The survival and the clinicopathologic variables regarding hMLH1 and hMSH2 expressions were assessed using the log-rank test and the Cox proportional regression method.
RESULTS
Either hMLH1 or hMSH2 expression was lost in nine cases (9.9%). hMLH1 and hMSH2 expressions were significantly correlated with tumor invasion (P=0.012) and tumor differentiation (P=0.017). The disease-free survival did not differ with respect to hMLH1 and hMSH2 expressions. The number of metastatic lymph nodes and the preoperative serum CEA level were independent predictors of disease-free survival on a multivariate analysis.
CONCLUSIONS
The loss of hMLH1 or hMSH2 expresscon appears to be involved in the differentiation of and the invasion by colon cancer. However, nether hMLH1 nor hMSH2 expression was correlated withthe 5-fluorouracil responsiveness.
Review
- New Trend in Chemotherapy for Colorectal Cancer.
- Kim, Young Jin , Kim, Hung Dai
- J Korean Soc Coloproctol. 2004;20(2):118-123.
- 1,143 View
- 3 Download
-
Abstract
PDF
- 5-Fluorouracil (5-FU) has been the main chemotherapeutic agent for the treatment of colorectal cancer for four decades with modest efficacy. Modulation of 5-FU by leucovorin or continuous infusion improves the response rate, but overall survival duration remains approximately 12 months. Many oral fluoropyrimidines have been studied, including capecitabine, UFT, S-1, and Eniluracil. Capecitabine has demonstrated equivalent efficacy with 5-FU and has been approved as first line treatment. CPT-11 demonstrated non-crossover resistance with 5-FU and was proven to be effective treatment for patients who received prior 5-FU. CPT-11 in combination with 5-FU has demonstrated improved response rate and overall survival duration over 5-FU or CPT-11. Oxaliplatin plus 5-FU has offered another effective treatment option for colorectal cancer. Both 5-FU plus leucovorin in combination with CPT-11 or oxaliplatin are widely used first-line chemotherapies for advanced colorectal cancer. The combinations of capecitabine with CPT-11 or oxaliplatin are being developed. Several molecular targeting agents such as EGFR inhibitors and antiangiogenic agents have developed. Cetuximab induces a broad range of cellular responses in tumors expressing EGFR, enhancing sensitivity to radiotherapy and chemotherapeutic agents. A key angiogenic pathway in the stimulation of tumour growth is the vascular endothelial growth factor (VEGF) pathway, inhibited by the monoclonal antibody bevacizumab. Phase II first line and phase III second line studies of oxaliplatin in combination with bevacizumab are now in progress. Optimal combinations and sequences of treatment are being studied, since several effective regimens have become available.
Original Articles
- Clinical Effects of Chemotherapy Combined with Interferon-alpha in Colorectal Cancer.
- An, Chang Hyeok , Park, Sang Hyub , Kang, Won Kyung , Oh, Seong Tack , Kim, Jeong Soo , Jeon, Hae Myung , Yoo, Seung Jin
- J Korean Soc Coloproctol. 2003;19(4):236-242.
- 1,211 View
- 2 Download
-
Abstract
PDF
- PURPOSE
In advanced colorectal cancer, 5-Fluorouracil (5-FU) and Leucovorin (LV) have been used as a standard chemotherapy regimen. 5-FU is a popular chemotherapeutic drug for colorectal cancers and LV is the most effective modulator of 5-FU. Recently, some studies using Interferon (INF) combination therapy with 5-FU to enhance the anti-tumor effect of 5-FU have been performed. The outcomes were reportet to be better than those of studies using single agent therapy. However, the clinical effect of a combination therapy with INF is still controversial. So that, we performed this study to understand the advantages of INF combination therapy in advanced colorectal cancers in the Korean population.
METHODS
We recruited patients who had been diagnosed with for colorectal cancers and received operations and postoperative adjuvant chemotherapy in Uijongbu St. Mary's hospital, from July, 1995, to June, 1999. The patients were divided into two groups; control group treated with the Mayo clinic chemotherapy regimen of 5-FU plus LV, and study group treated with additional INF-alpha to 5-FU-LV combination treatment. We evaluated the clinical outcomes such as the overall survival rate, the recurrence rate, and the chemotoxicity between two groups.
RESULTS
In comparison of 5 year survival rates of two groups for each stage of the colorectal cancer, those of stage B2 were 90.9% in the control group and 80.0% in the study group. For stage C patients, the values were 80.2% in control group and 52.5% in the study group. The overall 5-year survival rates of the control group and the study group regardless of stages were 77.1%, and 63.4%, respectively. The 5-year disease-free survival rates for stage B2 were 82.8% in the control group and 72.9% in the study group. For stage C patients, those were 42.6% in the control group and 34.4% in the study group. The recurrence and metastatic rates were 19.2% (local recurrence; 2, metastasis; 12) in the control group and 36.1% (local recurrence; 3 metastasis; 27) in the study group. The overall incidences of chemotoxicity were 24.7% in the control group and 31.3% in the study group.
CONCLUSIONS
There was no evidence that chemotherapy using 5-FU and LV combined with INF-alpha in advanced colorectal cancer patients was more effective than the Mayo regimen of 5-FU and LV. More large scale clinical studies are warranted to evaluate the efficacy of additional INF therapy in colorectal cancer patients.
- Clinical Trial of Oxaliplatin, 5-Fluorocuracil, and Leucovorin in Advanced Colorectal Cancer: 48 Cases.
- Lee, Seung Hyun , Ahn, Byung Kwon , Baek, Sung Uhn
- J Korean Soc Coloproctol. 2002;18(6):402-407.
- 1,366 View
- 19 Download
-
Abstract
PDF
- PURPOSE
Although 5-fluorouracil (5-FU) has been used as the basis of chemotherapy regimen for colorectal cancer for more than 40 years, 5-FU as single agent treatment has rarely achieved objective response rates higher than 15% in advanced colorectal cancers. The modulation of 5-FU with biologic modifiers has resulted in higher response rates, but survival advantages was not meaningful. Oxaliplatin is one of the newly developed drugs with proven activity against colorectal cancer. To evaluate the therapeutic efficacy and safety profile of oxaliplatin, we reviewed patients who received oxaliplatin chemotherapy.
METHODS
We reviewed 48 patients who received combination chemotherapy with oxaliplatin, 5-FU, and leucovorin (LV) from Jan. 2000 to Dec. 2001. The combination chemotherapy consisted of oxaliplatin (85 mg/m2 on day 1) as a 2~6 hour infusion followed by continuous infusion of 5-FU (1,500 mg/m2 on day 1, 2), concurrently with LV (45 mg on day 1, 2) as a 2 hour infusion. The combination chemotherapy interval was 2 weeks.
RESULTS
Of the 48 patients who received the combination chemotherapy with oxaliplatin, 5-FU, and LV, 25 cases were male, 23 cases were female. The median age was 51.4 years. The primary tumor sites were colon in 22 cases, and rectum in 26. According to TNM stage at diagnosis, 1 case was stage I, 5 cases were stage II, 21 cases were stage III, and 21 cases were stage IV. The metastatic sites were liver in 29 cases, lung in 10, pelvis in 7, peritoneum in 5, bone in 1, lymph node in 1, and spleen in 2. Previous chemotherapy were Mayo regimen in 43 patients, irrinotecan in 1 patient. Four patients had not received previous chemotherapy. Previously of the 48 patients, we could assess the chemotherapy response for 25 cases. Complete response was not observed. Partial response was 3 cases (12%), stable disease in 12 cases (48%), progressive disease in 10 cases (40%). From 227 cycles analyzed, the main toxicity was gastrointestinal one. Peripheral neuropathy was identifed in 5 cases.
CONCLUSIONS
We reviewed 48 patients with advanced colorectal cancer who received combination chemotherapy with oxaliplatin, 5-FU and LV. Of the 25 evaluable patients, the objective response rate was 12%. In our study, the combination chemotherapy with oxaliplatin, 5-FU, LV has not resulted in improved response rate, but overall toxicity was acceptable.
First
Prev- Page of 1
- Next
- Last
TOP
